Master-Studiengang Medical and Pharmaceutical Biotechnology

Sie suchen nach einem international anerkannten Master-Studiengang, der interessante Karrierechancen in der pharmazeutischen Industrie und in der Forschung eröffnet? Die breite Ausrichtung unseres Studiengangs Medical and Pharmaceutical Biotechnology wird von potenziellen Arbeitgebern besonders geschätzt.

Im Master-Studium vertiefen Sie Ihre Methoden- und Problemlösungskompetenz, um für die Herausforderungen bei der Entwicklung und Produktion von innovativen Therapeutika gegen Krebs, Autoimmun- oder neurodegenerative Erkrankungen gerüstet zu sein. Eingesetzt werden moderne und interdisziplinäre Methoden. Ein Beispiel: das „Züchten von Mini-Tumoren“, um die Wirkung von Krebsmedikamenten auf Patientinnen und Patienten leichter vorhersagen zu können.

Das Studium

Das englischsprachige Master-Studium Medical and Pharmaceutical Biotechnology dauert 4 Semester und ist darauf ausgelegt, den Studierenden fundiertes Wissen der medizinischen Biotechnologie und Fertigkeiten und Kompetenzen für die Entwicklung und Produktion biotechnologischer Produkte zu vermitteln.

Ein interdisziplinärer Zugang ist für den Erfolg in der Biotechnologie unerlässlich. Daher beschäftigen Sie sich verstärkt mit den naturwissenschaftlichen, medizinischen und technischen Zusammenhängen. Darüber hinaus vertiefen Sie Ihr Wissen über qualitätssichernde Rahmenbedingungen. Sie lernen, wie Sie die Erkenntnisse aus all diesen Disziplinen zusammenführen können.

Auch aktuelle Trends und Entwicklungen stehen auf dem Studienplan: zum Beispiel werden moderne Technologien wie „shotgun proteomics“ eingesetzt, um gestützt durch eine bioinformatische Auswertung die Gesamtheit der Proteine einer Zelle unter normalen und pathologischen Bedingungen zu untersuchen.

Lehrende von europäischen Universitäten, internationale Vortragende aus der pharmazeutischen Industrie und zahlreiche Laborpraktika stellen eine praxisorientierte Ausbildung, die an die Anforderungen der Industrie angepasst ist, sicher. Nach dem Studium stehen Ihnen alle Wege offen: Aufgrund der internationalen Ausrichtung des Studiengangs eröffnen sich Jobmöglichkeiten im In- und Ausland.

Besonders interessant: Gemeinsam mit der Faculty of Medicine and Health Sciences der schwedischen Linköping University bieten wir ein Dual Degree an. Zusätzlich zum Master of Science an der IMC FH Krems kann Ihnen der Abschluss des Studiengangs Experimental and Medical Biosciences an unserer Partner-Hochschule verliehen werden.

Studium Medical and Pharmaceutical Biotechnology - Studierende steht hinter einer Glasfront und pipettiert

Studium Medical and Pharmaceutical Biotechnology - 2 Mitarbeiter vor einem Computer

Studium Medical and Pharmaceutical Biotechnology - 2 Studierende stehen im Labor

" Nach Abschluss Ihres Studiums können Sie als Absolventin oder Absolvent in der internationalen Biotechnologiebranche oder in Doktoratsprogrammen Fuß fassen. "
Studiengangsleiter Harald Hundsberger

Erfolgskonzept: Theorie + Praxis

Das Studium umfasst 3 Säulen:

1
1. Die Kernbereiche
In den Semestern 1-2
Anstatt sich wie im Bachelor-Studium Medical and Pharmaceutical Biotechnology stark auf das Grundlagenwissen in den Naturwissenschaften zu fokussieren, geht das Master-Studium auf die Methoden- und Problemlösungskompetenz in der medizinischen und pharmazeutischen Biotechnologie ein.
In den ersten beiden Semestern wird das Vorwissen aus dem Bachelor-Studium oder einer entsprechenden Ausbildung vertieft. Module wie Health, Disease and Therapeutical Strategies, Process Design, Bioprocess Technology und Analytical Methods in Life Sciences stehen auf dem Studienplan. Zudem beginnen Sie im 1. Semester mit der Vorbereitung auf Ihr Research Semester.
Außerdem veranstaltet das Institut Biotechnologie einmal im Jahr das Life Science Meeting. Dabei handelt es sich um eine wissenschaftliche Konferenz, die bewusst sehr breit aufgestellt ist. Internationale Konferenzatmosphäre pur: Sie profitieren von international anerkannten Wissenschaftlerinnen und Wissenschaftlern aus Forschung und Industrie. Auch Studierende und Absolventinnen und Absolventen werden als Speaker integriert.
2
2. Die Spezialisierungen
In den Semestern 1-4
Bereits im 1. Semester haben Sie die Möglichkeit, den Schwerpunkt Ihres Studiums ganz nach Ihren persönlichen Interessen zu gestalten. Die Spezialisierungen Bioprocess Engineering und Advanced Therapeutics Development stehen zur Auswahl.
Sie verschaffen sich unter anderem einen Überblick über die aktuelle Forschungslandschaft: Zahlreiche Forschungsprojekte, die den 2 Spezialisierungen bzw. Forschungsschwerpunkten zugeordnet sind, werden im Rahmen der Spezialisierungen präsentiert.
Nützen Sie die Gelegenheit, um zur Expertin oder zum Experten auf dem Gebiet Ihrer Wahl zu werden: Die gewählte Spezialisierung trägt zur Feinjustierung Ihres beruflichen Profils bei. Im besten Fall entscheiden Sie sich also auch im Forschungssemester für eine Praktikumsstelle und ein Forschungsthema in dem gewählten Gebiet.
3
3. Das Research Semester und die Master-Arbeit
In den Semestern 3-4
Die Forschungsphase ist ein Kernelement des Master-Studiums. Sie können bereits nach dem 2. Semester mit der Forschungsarbeit für die Master-Arbeit beginnen, da die Vorlesungen des 3. und 4. Semesters online stattfinden, und damit bis zu einem Jahr in einem renommierten Biotechnologie-Unternehmen oder einer Forschungseinrichtung im In- oder Ausland verbringen. Beispiele sind das Massachusetts Institute of Technology (MIT) in den USA oder die Karolinska Universität in Schweden. Der Schwerpunkt Ihrer Arbeit wird ein Projekt sein, das die Grundlage für Ihre Master-Arbeit bildet.
Nach Ihren Research Semestern müssen Sie nur noch für die Master-Abschlussprüfung an die IMC FH Krems zurückkehren. Wenn Ihnen also Ihre Praktikumsgeberin oder Ihr Praktikumsgeber eine Festanstellung oder eine Doktorandenstelle anbieten, steht Ihnen nichts mehr im Wege.

Studienplan

Was wird Sie im Studium genau erwarten? Der Studienplan gibt Ihnen eine Übersicht.
Klicken Sie auf die einzelnen Lehrveranstaltungen um nähere Informationen zu erhalten.

Course	SWS	ECTS
Health, Disease and Therapeutical Strategies
Immunology	2	3
Immunology Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: IMM1VO Contact hours per week: 2 ECTS: 3 Course Content: Basic techniques for laboratory-based scientific work Safety training and working with safety data sheets Introduction to laboratory equipment (glassware, etc.) Using laboratory equipment (e.g. scales, pH meters and spectrophotometers) Basic laboratory techniques Handling acids, bases and organic solvents Working with indicators Producing solutions and serial dilutions; calculating concentrations and estimating errors Course outcome: Upon completion of this course students are able to: explain the complex physiology of the immune system, summarize the activation of immune cells by pathogens in terms of mechanisms and systems, explain the complex function of the human immune system.
Hallmarks of Cancer	1	1
Hallmarks of Cancer Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: HOC1VO Contact hours per week: 1 ECTS: 1 Course Content: The history of cancer research Molecular causes of cancer Genetic changes and their causes Fundamental molecular features of cancer development Multi-stage process of cell transformation Tumour-stromal interactions Metastasis Tumour immunology Tumour metabolism Targeted therapies and personalised medicine Tumour engineering and drug development Course outcome: Upon completion of this course students are able to: explain the molecular causes of cancer, explain and analyze the complex events when healthy tissue is transformed into malignant tissue, explain and interpret new therapeutic approaches aimed at treating cancer and immunological disorders.
Molecular Mechanisms of Ageing	1	1
Molecular Mechanisms of Ageing Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: MMA1VO Contact hours per week: 1 ECTS: 1 Course Content: The ageing process in cells The ageing process in living organisms Theories and molecular mechanisms of ageing Genetic programming for ageing Environmental factors and genetic predisposition Premature ageing: selected examples and molecular causes of the condition Lifestyle, stress and hormonal status Age-related diseases and their causes Course outcome: Upon completion of this course students are able to: explain the functional relationships between the genome, embryogenesis, ageing processes, environmental factors and diseases, explain and analyze the complex events in cells an tissues when aging takes place, explain the physiology of ageing and associated diseases.
Developmental Biology	1	1
Developmental Biology Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: DBIO1VO Contact hours per week: 1 ECTS: 1 Course Content: Fundamentals and mechanisms of embryogenesis Early embryogenesis and topological patterning of the axes (fertilisation, initial cell division, morula, gastrulation and neurulation) Late embryogenesis (organ development from ectoderm, mesoderm and endoderm) Embryonic models for drug development Somatic cell reprogramming and regenerative medicine Course outcome: Upon completion of this course students are able to: analyze the functional relationships between the genome, embryogenesis, ageing processes, environmental factors and diseases, explain the molecular mechanisms of embryogenesis, use embryonic animal models for testing active ingredients.
Bioethics
Bioethics	1	1
Bioethics Module: Bioethics Root module: Bioethics Semester: 1 Course code: BETH1WK Contact hours per week: 1 ECTS: 1 Course Content: The ethics of end-of-life decision making Embryo screening Predictive medicine Transplantation medicine Legal issues Stem cells Assisted dying Moderated discussions on relevant topics Course outcome: Upon completion of this course students are able to: evaluate and discuss social and scientific aspects of applications of genetic engineering as well as bioethical issues, evaluate and find solutions to legal questions related to bioethics, evaluate and apply statutory regulations connected with bioethics and human dignity.
Process Design
Equipment and Production Design	2	3
Equipment and Production Design Module: Process Design Root module: Process Design Semester: 1 Course code: EPD1VO Contact hours per week: 2 ECTS: 3 Course Content: •Specifications (facilities, product, instrumentation), analytical systems (e.g. sensors) Costing and design of utility systems (gas and air supply, water for injection, cooling and heating mediums) IQ, OQ, PQ, URS, process qualification Inspection, acceptance and commissioning of production facilities (cleaning, water runs, sterility and conformity testing) Process standards Media design (complex, defined) including media preparation and sterilisation techniques (in situ, ex situ) Inoculum preparation and fermentation management; microbial organisms vs. mammalian cells Fermentation kinetics (e.g. product formation rate, glucose uptake rate, oxygen requirements and energy input) Students independently complete exercises on media preparation planning, calculation of parameters for reaction kinetics, sterilisation times and microorganism kill rates, and for the efficiency of virus removal steps, as well as preparing sampling plans using the kinetics data to compile batch records. Course outcome: Upon completion of this course students are able to: plan the basic features of biotechnology production facilities, explain standards and families of standards applicable in Austria and abroad, and interpret them accordingly, apply integrated knowledge of production facility design to achieve precisely defined product quality parameters.
Standardization	1	2
Standardization Module: Process Design Root module: Process Design Semester: 1 Course code: ST1VO Contact hours per week: 1 ECTS: 2 Course Content: Overview of the development of company specification standards based on national and international standards Specifications Standards (open, proprietary, basic, product, planning and service) Distinction between specifications, standards, regulation and company standards The standardisation process National standards (ÖNORM, DIN) International standards (ISO, CEN) Structural design of standards Dealing with national and international standards in the course of routine work in the biotechnology industry Legal aspects of standardisation Distinction between standardisation and accreditation The accreditation process Course outcome: Upon completion of this course students are able to: explain standards and families of standards applicable in Austria and abroad, and interpret them accordingly, explain and apply legal aspects of product standardisation based on national and international standards.
Biomedical Regulatiuons
Legislation for Drugs and Medical Devices	2	3
Legislation for Drugs and Medical Devices Module: Biomedical Regulatiuons Root module: Biomedical Regulatiuons Semester: 1 Course code: LDMD1VO Contact hours per week: 2 ECTS: 3 Course Content: Pharmaceuticals legislation in Europe and the US Definition of pharmaceuticals and important distinctions Development and lifecycles of pharmaceuticals Quality aspects of pharmaceuticals, safety and efficacy Structure and content of specialist and patient information Pharmaceuticals approval process in Europe and the US Maintaining approval Generic drugs, internet and product liability Pharmacovigilance Pharmaceuticals marketing and sales Medical Products Act: requirements for medical products (harmonised standards, CE marking, carrying out conformity assessments) Classification of medical products Course outcome: Upon completion of this course students are able to: apply the legislation and related regulatory regimes for pharmaceuticals in Europe and the US (EMDA, FDA), apply statutory guidelines and patent restrictions pertaining to biomedical products during their lifecycle.
Bioprocess Technology
Upstream and Downstream Processing
Upstream Processing	1	2
Upstream Processing Module: Upstream and Downstream Processing Root module: Bioprocess Technology Semester: 1 Course code: UP1VO Contact hours per week: 1 ECTS: 2 Course Content: Students learn about the processes involved in preparing and managing fermentation with microbiological organisms and mammalian cells. The lectures will cover: • Different useful Host Organisms, their advantages and disadvantages • Fermentation kinetics (e.g. product formation rate, glucose fermentation rate, oxygen requirements and energy input) • Calculations describing fermentations (Mass Balancing, Feed Calculations, Heat Generation and Dissipation) • Fermentation process development and scaling based on different parameters Students perform calculations of parameters for reaction kinetics, feeding and heat dissipation based on typical sets of information given in the industrial environment. Course outcome: Upon completion of this course students are able to: explain technical equipment requirements and process parameters, and classify their application principles.
Downstream Processing	1	2
Downstream Processing Module: Upstream and Downstream Processing Root module: Bioprocess Technology Semester: 1 Course code: DP1VO Contact hours per week: 1 ECTS: 2 Course Content: Students learn about the processes involved in preparing and managing downstream processes of recombinant products comming from microbiological organisms and mammalian cells. The lectures will cover: Cell breakup Primary recovery Different separation principles (mainly chromatography but also christallization) and their scaling preparation for fill and finish Course outcome: Upon completion of this course students are able to: explain and design primary recovery steps, design downstream processes including several purification steps, explain the scaling of primary recovery and purification, design preparation for fill and finish.
Recombinant Protein Production - Theory	2	3
Recombinant Protein Production - Theory Module: Bioprocess Technology Root module: Bioprocess Technology Semester: 1 Course code: RPPT1ILV Contact hours per week: 2 ECTS: 3 Course Content: Overview of the most frequently used protein production organisms for research and industrial applications General principles of protein production Impact of biochemical properties of proteins, their amino acids and chemical modifications on protein production and protein purification Comparison and discussion of standard protein purification strategies Course outcome: Upon completion of this course students are able to: name the principles of the key methods of protein purification and compare their advantages and disadvantages, compare biopharmaceutical production and/or purification strategies.
Recombinant Protein Production - Laboratory	4	4
Recombinant Protein Production - Laboratory Module: Bioprocess Technology Root module: Bioprocess Technology Semester: 1 Course code: RPPL1LB Contact hours per week: 4 ECTS: 4 Course Content: Demonstration of the principles of gene expression/protein production in the Pichia pastoris production organism demonstrated using a cytokine Purification of a cytokine Using this protein to learn about typical methods of biochemical analysis for the characterisation of proteins Specific content includes transformation of yeast cells, expression of cytokine genes from an inducible promoter, breaking open cells and obtaining cell extract, purification of the desired protein using affinity chromatography, defining the protein concentration, visualisation of the protein using western blotting, tests to characterise the bioactivity of the protein. Course outcome: Upon completion of this course students are able to: apply their knowledge of the points above in a laboratory environment, independently develop biopharmaceutical production and/or purification strategies.
Research Project in Industry and Master Thesis
Research Project - Preparation	1	1
Research Project - Preparation Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 1 Course code: RPP1WK Contact hours per week: 1 ECTS: 1 Course Content: Updating CVs and covering letters Career and internship opportunities in industry and research Coaching support with research semester applications Course outcome: Upon completion of this course students are able to: develop arguments to support an application and write application documents, identify and analyse the requirements of prospective employers or internship providers, select research projects suited to their chosen future career, evaluate possible future career paths.
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Process Control and Process Online Monitoring	2	3
Process Control and Process Online Monitoring Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 1 Course code: S1_PCPOM1VO Contact hours per week: 2 ECTS: 3 Course Content: Theoretical principles and technical options in process control Theoretical principles of the measurement, control, regulation, properties and operation of probes Selecting and monitoring critical measurement parameters Automated process definition Process mapping Input-process-output diagrams Process flow diagrams Value stream mapping Top-down charts Swimlane diagrams Process performance Process capability and stability Cp and Cpk Sigma quality levels Simulation calculations and practical exercises Course outcome: Upon completion of this course students are able to: explain the monitoring of up-to-date production processes, identify appropriate instrumentation for the online control and monitoring of processes.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Drug Discovery Systems	2	3
Drug Discovery Systems Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 1 Course code: S2_DDS1VO Contact hours per week: 2 ECTS: 3 Course Content: Biochemical and biophysical assays for drug discovery 3D cell culture techniques for drug discovery Development of small molecular weight compounds High-throuput- and high-content screening Marine organisms as sources of new therapeutic agents Course outcome: Upon completion of this course students are able to: explain major principles applied in drug discovery, compare cutting edge drug discovery methods, illustrate and compare methods of characterising newly discovered drugs, summarize the different phases of the drug discovery process.

Course	SWS	ECTS
Integrative Methods in Biotechnology
Biostatistics and Trend Analysis	1	2
Biostatistics and Trend Analysis Module: Integrative Methods in Biotechnology Root module: Integrative Methods in Biotechnology Semester: 2 Course code: BTA2ILV Contact hours per week: 1 ECTS: 2 Course Content: Precision and reliability of confidence limits Significance tests (T-tests, chi squared test, F-test and non-parametric alternatives) Variance analysis (parametric and non-parametric) Trend analysis Analysis of contingency tables Course outcome: Upon completion of this course students are able to: use biostatistics to address common biotechnology questions, explain physical values that have a significant effect on biotechnological processes.
Systems Biology	1	1
Systems Biology Module: Integrative Methods in Biotechnology Root module: Integrative Methods in Biotechnology Semester: 2 Course code: SBIO2ILV Contact hours per week: 1 ECTS: 1 Course Content: The concept of systems biology Areas of overlap with other disciplines and network theories Forthcoming high-throughput technologies Interactions between components of cellular systems Applications of systems biology strategies for the development of therapies and identification of drug targets Course outcome: Upon completion of this course students are able to: explain the complex interactions of biomolecular networks, explain methods for analysing biomolecular networks.
Structural Bioinformatics and Drug Design	2	2
Structural Bioinformatics and Drug Design Module: Integrative Methods in Biotechnology Root module: Integrative Methods in Biotechnology Semester: 2 Course code: SBDD2VO Contact hours per week: 2 ECTS: 2 Course Content: Biomolecules: basic biochemical and biophysical principles Structural alignment of biomolecules Experiment-based structural determination of biomolecules Predicting biomolecular structural features Modelling the 3D structure of biomolecules Principles and common methods of drug design Course outcome: Upon completion of this course students are able to: examine the links between the structure and function of biomolecules, analyse and compare the 3D structure of biomolecules, use calculations for properties of biomolecules, apply selected drug design methods.
Analytical Methods in Life Science
Bioanalytics Laboratory	2	3
Bioanalytics Laboratory Module: Analytical Methods in Life Science Root module: Analytical Methods in Life Science Semester: 2 Course code: BAL2LB Contact hours per week: 2 ECTS: 3 Course Content: Mass spectroscopy gene knock down with siRNA in mammalian cells followed by analysis of the proteome bioinformatic analyis of proteomic data gene clustering and visualization of pathways identification of putative targets Course outcome: Upon completion of the course, students are able to: apply practical organic separation and detection skills and synthesise simple organic compounds, apply documentation on synthesis reactions and estimate the related risks.
Personalized Medicine Laboratory	2	3
Personalized Medicine Laboratory Module: Analytical Methods in Life Science Root module: Analytical Methods in Life Science Semester: 2 Course code: PML2LB Contact hours per week: 2 ECTS: 3 Course Content: DNA and RNA isolation and analysis cDNA synthesis Real-time quantitative PCR (qPCR) with SYBR® Green and TaqMan™ probes (comparison) Gene expression analysis Allele-specific qPCR SNP analysis High-resolution melting curve analysis PCR RFLP Pyrosequencing Course outcome: Upon completion of this course students are able to: apply practical organic separation and detection skills and synthesise simple organic compounds, apply documentation on synthesis reactions and estimate the related risks.
Analytical Methods in Biomedicine	2	3
Analytical Methods in Biomedicine Module: Analytical Methods in Life Science Root module: Analytical Methods in Life Science Semester: 2 Course code: AMB2VO Contact hours per week: 2 ECTS: 3 Course Content: Methods of real-time qPCR (including primer design in the PC lab) and their applications (gene expression analysis, allele-specific qPCR) Methods of identifying genetic variations (e.g. sequencing, pyrosequencing and massive parallel sequencing) – personalised medicine Analysis of epigenetic modifications DNA-protein interactions (ChIP, EMSA, DNase footprint) Flow cytometry Cell fractionation Analysis of post-translational modifications (phosphorylation, glycosylation, ubiquitination) Course outcome: Upon completion of this course students are able to: explain gene expression analyses at the RNA and protein levels, and present them in academic texts, explain epigenetic modifications and formulate hypotheses on their effects, explain methods of practical organic separation.
Fundamentals in Pharmaceutical Sciences
Pharmacokinetics and Pharmacodynamics	2	3
Pharmacokinetics and Pharmacodynamics Module: Fundamentals in Pharmaceutical Sciences Root module: Fundamentals in Pharmaceutical Sciences Semester: 2 Course code: PP2VO Contact hours per week: 2 ECTS: 3 Course Content: General pharmacology Quantifying the effects of pharmaceuticals Concentration-effect relationships for in vitro and in vivo models Characterisation of agonists and antagonists Molecular mechanisms of action and target proteins in pharmaceuticals Types of receptor, receptor subtypes, pharmacodynamic and pharmacokinetic causes of resistance Pharmacological studies in preclinical pharmaceutical development Use of animal models Pharmacological studies in clinical development ADME: fundamental principles of resorption, distribution, metabolism, and excretion of pharmaceuticals Determining ADME parameters in practice Phases of clinical trials Preparation of investigator's brochures Course outcome: Upon completion of this course students are able to: compare the principles and key areas of pharmacodynamics and pharmacokinetics, analyse pharmacodynamic and pharmacokinetic parameters, explain the molecular mechanism of action of pharmaceuticals, evaluate the role of pharmacodynamics and pharmacokinetics as part of pharmaceutical development, summarize how animal models are used in pharmacology.
Quality Management and Regulations in Biotechnology
GLP, GMP and Risk Assessment
GLP and GMP Regulations	1	1
GLP and GMP Regulations Module: GLP, GMP and Risk Assessment Root module: Quality Management and Regulations in Biotechnology Semester: 2 Course code: GGR2VO Contact hours per week: 1 ECTS: 1 Course Content: Statutory quality assurance regulations in the pharmaceutical industry OECD Principles of Good Laboratory Practice (GLP); applicability of the study plan and study report EU Guide to GMP and CFR 210/211; applicability of the GMP regulation Setting up a product facility Regulations relating to personnel, production, documentation, quality control and QM QM during the biotechnological development process Testing of active substances and additives Formulation development, developing production processes; form of administration and container closure systems Microbial controls; compatibility QM in the pharmaceutical industry: ICH Q8,Q9 and Q10 Course outcome: Upon completion of this course students are able to: name and apply statutory pharmaceutical quality assurance regulations applicable in the preclinical, clinical and production phases, explain and apply audit systems.
Risk Assessment	1	1
Risk Assessment Module: GLP, GMP and Risk Assessment Root module: Quality Management and Regulations in Biotechnology Semester: 2 Course code: RA2VO Contact hours per week: 1 ECTS: 1 Course Content: Risk management in accordance with ICH Q9 and other guidelines Methods of risk assessment: preliminary risk analysis: Preliminary hazard analysis (PHA), event tree analysis (ETA), failure mode and effect analysis (FMEA), fault tree analysis (FTA), HAZOP (hazard and operability studies) Corrective measures: HAZOP Critical control point hazard analysis and critical point methodology (HACCP) Risk management and reliability planning, risk assessment for development projects, environmental risk assessment Course outcome: Upon completion of this course students are able to: apply various risk assessment methods in the context of the pharmaceutical and biotechnology industries.
Quality Management Systems	1	1
Quality Management Systems Module: Quality Management and Regulations in Biotechnology Root module: Quality Management and Regulations in Biotechnology Semester: 2 Course code: QMS2VO Contact hours per week: 1 ECTS: 1 Course Content: Quality management systems, standards and guidelines, comparison of ISO, ICH and GMP Statistical methods and elements of QM Principles of QM and its elements Auditing quality management systems; principles and methods Course outcome: Upon completion of this course students are able to: explain and interpret quality assurance methods for pharmaceutical products, explain various aspects of quality management (QM) systems, apply and analyse statistical methods for QM systems, explain and apply audit systems.
Pharmaceutical Project Management
Project and Portfolio Management	1	1
Project and Portfolio Management Module: Pharmaceutical Project Management Root module: Pharmaceutical Project Management Semester: 2 Course code: PPMGT2VO Contact hours per week: 1 ECTS: 1 Course Content: Key aspects of project management in the pharmaceutical industry Portfolio management Corporate strategy Project structure planning, work packages, project network diagrams, critical path analysis Managing integration Developing biotechnological pharmaceuticals Course outcome: Upon completion of this course students are able to: plan and implement pharmaceutical industry projects, generate project plans with work packages.
Clinical Studies and GCP	1	1
Clinical Studies and GCP Module: Pharmaceutical Project Management Root module: Pharmaceutical Project Management Semester: 2 Course code: CSGCP2VO Contact hours per week: 1 ECTS: 1 Course Content: Clinical trials: phases and management Setting up and monitoring clinical trials Quality standards for clinical trials Interface management during trials, academic versus industry-funded research Risk-benefit analysis Investigational product management Project management in clinical trials Course outcome: Upon completion of this course students are able to: evaluate the regulations applicable to particular clinical trials and apply them in the course of the respective project, devise a set-up for carrying out clinical trials.
Entrepreneurship in Life Sciences	2	2
Entrepreneurship in Life Sciences Module: Pharmaceutical Project Management Root module: Pharmaceutical Project Management Semester: 2 Course code: ELS2ILV Contact hours per week: 2 ECTS: 2 Course Content: Students will be introduced to the business side of setting up a new company and key management processes. Business aspects of start-ups: Analysis of the business environment (analysis of the market, environment, location as well as legal, political and technical considerations) Choice of legal form Drawing up a business plan Cost accounting: Designing a cost accounting and cost-type system Cost-centre accounting Cost unit accounting (calculation), analysis of operating profit Management control: Budgeting Budgets and financial plans Objectives, tasks and functions of management control Management indicators Analysing annual financial statements Management case studies Course outcome: Upon completion of this course students are able to: exemplify an overview of business processes, explain underlying legal frameworks, explain how business processes can be managed.
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Fermentation and Scale Up - Scale Down Techniques
Fermentation of Complex Host Systems	1	1
Fermentation of Complex Host Systems Module: Fermentation and Scale Up - Scale Down Techniques Root module: Elective 1: Bioprocess Engineering Semester: 2 Course code: S1_FCHS2VO Contact hours per week: 1 ECTS: 1 Course Content: Fermentation of extremophile organisms Co-cultivation of organisms Mammalian cell fermentation Use of alternative carbon (C) sources with specialised organisms New types of host systems (content selected by the available visiting experts) Course outcome: Upon completion of this course students are able to: analyse and optimise the progress of fermentation and solve problems that arise, operate a process control system and program simple operations.
Scale Up - Scale Down Techniques	1	2
Scale Up - Scale Down Techniques Module: Fermentation and Scale Up - Scale Down Techniques Root module: Elective 1: Bioprocess Engineering Semester: 2 Course code: S1_SUSDT2VO Contact hours per week: 1 ECTS: 2 Course Content: Purification steps for biopharmaceutical products and methods for shifting from laboratory-scale to pilot-plant or production scale processes The four main operations in downstream production: removal of insolubles, product isolation, product purification and product polishing Filtration, lysis and flocculation, sedimentation, extraction, chromatography and adsorption, precipitation, crystallisation, spray drying and centrifugation Dimensionless indicators and an introduction to dimensional analysis Calculation exercises: characterisation of individual purification steps and scaling up elements of facilities Application of scale-down models for process modelling to resolve problems with current production processes Course outcome: Upon completion of this course students are able to: explain common techniques and purification strategies for the production of biopharmaceuticals, explain key requirements for technical equipment, the key process parameters and their determination, as well as the adaptation of process strategies according to the production organism and the properties of the biopharmaceutical product, apply this knowledge in simple examples, analyse problems in relation to the areas mentioned above.
Fermentation Technology - Laboratory I	2	3
Fermentation Technology - Laboratory I Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 2 Course code: S1_FTLI2LB Contact hours per week: 2 ECTS: 3 Course Content: Fermentation of different host systems in different operational modes (Batch, Fed-Batch) Sampling (online, atline and offline) and corresponding analytics Analyzing and judging of analytical data Applying the theoretical knowledge and data to control and optimize the fermentation Primary recovery based on the fermentation process Purifying of recombinant proteins Course outcome: Upon completion of this course students are able to: explain and apply advanced fermentation knowledge to develop and optimize fermentation processes with different host organisms, explain and apply primary recovery knowledge to develop and optimize this process step, explain and apply purification of proteins knowledge to develop and optimize this process step.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Advanced Therapeutic Development Laboratory I	2	3
Advanced Therapeutic Development Laboratory I Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 2 Course code: S2_ATDLI2LB Contact hours per week: 2 ECTS: 3 Course Content: Establishment and validation of Assays for HCS High-throughput Screening: theoretical and practical programming of an HT device (liquid handling & automation Course outcome: Upon completion of this course students are able to: generate and validate complex Assays for HCS, explain, analyse and discuss the latest trends in HCS, programm and use a HT-device.
Pathophysiology and Molecular Therapies	2	3
Pathophysiology and Molecular Therapies Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 2 Course code: S2_PMT2VO Contact hours per week: 2 ECTS: 3 Course Content: Pathology of selected example illnesses State-of-the-art therapy strategies Developing new therapy concepts Standard strategies and future approaches to vaccination Development and application of the latest mouse models Course outcome: Upon completion of this course students are able to: explain/illustrate selected example illnesses and describe their pathophysiology, explain and compare state-of-the-art therapy strategies and new therapy concepts.

Course	SWS	ECTS
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Equipment Test and Process Validation	2	4
Equipment Test and Process Validation Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 3 Course code: S1_ETPV3VO Contact hours per week: 2 ECTS: 4 Course Content: <ul> <li>Fundamentals of equipment, test and process validation based on legal guidelines and using practical examples</li> <li>Design qualification</li> <li>User requirements specification</li> <li>Functional specifications</li> <li>Installation qualification (IQ), drawing up IQ plans</li> <li>Operational qualification (OQ)</li> <li>Drawing up OQ plans</li> <li>Performance qualification</li> <li>Retrospective qualification</li> <li>Requalification</li> <li>Maintaining qualification status</li> <li>Process validation</li> <li>Defining the scope of a validation, risk analysis</li> <li>Validation master plan and validation matrix</li> <li>Cleaning validation</li> <li>Optimising cleaning procedures and drafting cleaning policies</li> <li>Cleaning validation master plan</li> <li>Defining the scope of validation</li> <li>Acceptance criteria, computer validation</li> <li>Prospective and retrospective validation, validation master plan</li> <li>Operating computerised systems</li> </ul> Course outcome: Upon completion of this course students are able to: analyse offline analytical tests for the quality control of biopharmaceuticals, use the knowledge outlined above to optimise processes and identify and solve problems that arise in this context, design test documentation, use and plan equipment and devices in the context of pharmaceutical applications, design experimental designs and parameters for the validation of simple tests and items of equipment, design and evaluate test specifications and reports.
Fermentation Technology - Laboratory II	5	11
Fermentation Technology - Laboratory II Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 3 Course code: S1_FTLII3LB Contact hours per week: 5 ECTS: 11 Course Content: Fermentation of single cell organisms Operating process control systems Working with bioreactors under sterile conditions Offline measurement methods Online measurement methods Calculating fermentation control parameters Preparing defined and complex media Sterile addition methods Troubleshooting Analysis of fermentation parameters Evaluating parameters to arrive at a process management approach Setting up, dismantling and maintaining bioreactors Analytical methods of evaluation (e.g. electrophoresis, FPLC and ELISA) Cell disruption methods Course outcome: Upon completion of this course students are able to: explain basic and andvanced principles of fermentation and the use of fermentation technology in a near-industrial context, apply this knowledge to manage fermentation processes, use fermentation measurement data to inform subsequent process management decisions.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Stem Cells, Gene Therapy and Regenerative Medicine	1	3
Stem Cells, Gene Therapy and Regenerative Medicine Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 3 Course code: S2_SCGTRM3VO Contact hours per week: 1 ECTS: 3 Course Content: Stem cells for therapeutic applications Principles of cell and tissue therapy Principles of gene therapy and its applications Tissue engineering techniques Examples of cell and tissue therapy applications Course outcome: Upon completion of this course students are able to: identify and classify the properties of different types of stem cell, explain the therapeutic applications of stem cells and other types of cell, and discuss the latest trends in stem cell research.
Immunology Based Therapies	1	1
Immunology Based Therapies Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 3 Course code: S2_IBT3VO Contact hours per week: 1 ECTS: 1 Course Content: Key properties of immune cells for immune therapy Immune therapy techniques Examples of immune therapy application Course outcome: Upon completion of this course students are able to: compare therapeutic approaches in regenerative medicine, explain the principles of gene therapy and discuss their application, explain and compare strategies for immune-based therapies.
Advanced Therapeutic Development Laboratory II	5	11
Advanced Therapeutic Development Laboratory II Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 3 Course code: S2_ATDLII3LB Contact hours per week: 5 ECTS: 11 Course Content: Isolation and characterization of a state-of-the-art bioactive, therapeutic biomolecule Quality control of this product Characterisation of the product’s functionality (Cell-based Assays) Course outcome: Upon completion of this course students are able to: use methods for the isolation and characterization of therapeutic agents in the laboratory, examine their function of biomolecules using laboratory experiments, discuss the latest trends in the development of therapeutic agents, identify and evaluate potential fields of application.
Research Project in Industry and Master Thesis
Master Thesis - Part I	1	4
Master Thesis - Part I Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 3 Course code: MTI3DA Contact hours per week: 1 ECTS: 4 Course Content: Writing the proposal for the master thesis Practical work and data analysis Course outcome: Upon completion of this course students are able to: Write a master thesis proposal in accordance with the applicable guidelines, Perform the practical work, Analyze the achieved data, independently carry out a research project on a topical theme in a real-life business, biotechnology and/or biomedical working environment.
Master Thesis - Coaching Seminar I	1	1
Master Thesis - Coaching Seminar I Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 3 Course code: MTCI3TU Contact hours per week: 1 ECTS: 1 Course Content: Discussion, feedback and quality assurance of the master thesis proposal Course outcome: Upon completion of this course students are able to: prepare, plan and discuss a scientific project in an appropriate manner.
Research Project	1	10
Research Project Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 3 Course code: RP3SE Contact hours per week: 1 ECTS: 10 Course Content: Literature research Definition of topic for the master thesis Definition of Scientific Methods for the Master thesis Course outcome: Upon completion of this course students are able to: read and evaluate scientific literature, generate and plan a research project, independently carry out a research project on a topical theme in a real-life business, biotechnology and/or biomedical working environment.

Course	SWS	ECTS
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Current Issues in Bioprocess Engineering	1	2
Current Issues in Bioprocess Engineering Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 4 Course code: S1_CIBE4SE Contact hours per week: 1 ECTS: 2 Course Content: Literature research on the latest trends in the relevant fields Reviewing the relevant literature Presentation of results Discussion of the contents of the literature selected Course outcome: Upon completion of this course students are able to: explain the actual state of research in the corresponding field, apply their knowledge to the actual problems in research and industry.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Current Issues in Advanced Therapeutic Development	1	2
Current Issues in Advanced Therapeutic Development Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 4 Course code: S2_CIATD4SE Contact hours per week: 1 ECTS: 2 Course Content: Literature research on the latest trends in the relevant fields Reviewing the relevant literature Presentation of results Discussion of the contents of the literature selected Course outcome: Upon completion of this course students are able to: explain the actual state of research in the corresponding field, apply their knowledge to the actual problems in research and industry.
Research Project in Industry and Master Thesis
Master Thesis - Part II	1	18
Master Thesis - Part II Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 4 Course code: MTII4DA Contact hours per week: 1 ECTS: 18 Course Content: Practical work and data analysis Summary and evaluation of the scientific data in a master thesis Course outcome: Upon completion of this course students are able to: examine and critically discuss literature related to the topic or research problem, Perform the practical work, compile and evaluate data for the purpose of addressing the research problem/s, discuss and critically reflect on findings, independently complete a scientifc paper in form of the master thesis.
Master Thesis - Coaching Seminar II	1	6
Master Thesis - Coaching Seminar II Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 4 Course code: MTCII4TU Contact hours per week: 1 ECTS: 6 Course Content: Discussion, feedback and quality assurance of the master thesis proposal Course outcome: Upon completion of this course students are able to: prepare, plan and discuss a scientific project in an appropriate manner.
Master Exam	0	4
Master Exam Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 4 Course code: MEX4AP Contact hours per week: 0 ECTS: 4 Course Content: Presentation of the master thesis Oral examination on the Master thesis and links to related subjects on the curriculum Course outcome: Upon completion of this course students are able to: present their master thesis and the question they addressed in a manner appropriate to the target audience, and defend the thesis before an expert committee, outline the significance of the findings for professional practice and research, and present supporting arguments, answer follow-up questions on degree-programme subjects and the links between them, and justify their answers.

Spezialisierungen

Setzen Sie Ihre eigenen Schwerpunkte: Im Studium entscheiden Sie sich für 1 von 2 Electives.

Bioprocess Engineering

Diese Spezialisierung bereitet Sie auf die Entwicklung und Produktion von pharmazeutischen Produkten vor.

Diese Produkte werden heutzutage oft biopharmazeutisch, also durch Fermentation in großen Bioreaktoren, hergestellt. Hierbei kommen genetisch modifizierte Mikroorganismen zum Einsatz, die in sehr hohen Zelldichten gezüchtet werden und das gewünschte Produkt herstellen. Die Produktpalette reicht hier von Medikamenten über Nahrungsmittel-Ergänzungsstoffe bis zu Stoffen wie Bioethanol.

Durch die Spezialisierung erwerben Sie vertiefte Kenntnisse über Bioverfahrenstechnik, Prozessautomatisierung und vor allem Fermentation. Dieses Know-how befähigt Sie, in allen biotechnologischen Unternehmen zu arbeiten – sowohl in großen pharmazeutischen Firmen als auch in kleinen Start-ups, die sich auf neuartige Produkte wie Nutraceuticals spezialisiert haben. Ihr Einsatzgebiet reicht von der Entwicklung ganz neuer Substanzen über die Testung derselben bis hin zur Herstellung im großen Maßstab für den Markt.

Unterstützt werden die Bioverfahrenstechnik-Vorlesungen und Übungen durch den Einsatz moderner analytischer Methoden. Hier reicht das Spektrum von einfachen Online-Methoden und deren Auswertung bis zu Proteomics mittels HPLC-MS.

Advanced Therapeutics Development

Diese Spezialisierung beschäftigt sich mit der wissenschaftlichen Erforschung von Wirkstoffen und deren Mechanismen. Dadurch ist sie die perfekte Grundlage für ein weiterführendes PhD-Studium oder für einen Job in der F&E Abteilung in der Biotechnologie-Industrie.

In der medizinischen Biotechnologie gab es in den letzten Jahren bahnbrechende Erfolge. Ein Beispiel: die Immun-Checkpoint-Inhibitoren (PD1) bei der Behandlung von fortgeschrittenen Melanomen. Zurzeit werden siRNA-Moleküle, kleine, eingreifende RNA-Einheiten, auf ihre Wirksamkeit bei der Behandlung von Krebs- und Viruserkrankungen überprüft; Zulassungen sind hier in den nächsten Jahren zu erwarten.

Die Entwicklung neuer Therapien wird zunehmend durch Entwicklungen im Bereich von Hochdurchsatz-Technologien wie „Next Generation Sequencing“ (NGS), Massenspektroskopie und bildgebende Verfahren geprägt. Darum wird es in Zukunft immer mehr notwendig sein, große Datensätze miteinander zu verknüpfen und klinische Ergebnisse aus der Therapie miteinzubeziehen.

Die Module in der Spezialisierung Advanced Therapeutic Development geben hier einen fundierten Bezug. Gestützt wird dies durch ein Spezialisierungslabor, in dem die frühe Phase der Entwicklung eines Therapeutikums nachvollzogen wird. Ein Journalclub zu aktuellen Problemen der Biotechnologie rundet das Programm ab.

Newsletter & Infomaterial

Zusätzliche Informationen gefällig? Abonnieren Sie Ihren personalisierten Newsletter oder bestellen Sie Broschüren über unsere Studiengänge direkt zu sich nach Hause.

Jetzt zusätzliche Informationen anfordern

Broschüre jetzt downloaden

Newsletter & Infomaterial

Themen

Vorname *

Dieses Feld darf nicht leer sein.

Nachname *

Dieses Feld darf nicht leer sein.

E-Mail *

Dieses Feld darf nicht leer sein.

Sprache

Ja, ich möchte die von mir ausgewählten Informationen vom IMC Krems erhalten. *

Dieses Feld darf nicht leer sein.

Die mit * makierten Felder sind Pflichtfelder und müssen ausgefüllt werden. Ihre Daten werden selbstverständlich vertraulich behandelt. Wenn Sie sich zum Newsletter anmelden, werden Ihre Daten auch von unserem Auftragsverarbeiter in den USA (MailChimp) verarbeitet. In den USA herrscht kein angemessenes Datenschutzniveau. US-Behörden haben eventuell Zugriff auf Ihre Daten, ohne dass Sie eine adäquate Möglichkeit des Rechtsschutzes haben. Bitte finden Sie die Details zur Verarbeitung Ihrer personenbezogenen Daten in der Datenschutzerklärung insbesondere unter dem Punkt „Newsletterversand“.

* Mandatory fields must be completed. Your data will be treated confidentially. If you register for the newsletter, your data will also be processed by our data processor in the USA (MailChimp). There is no adequate level of data protection in the USA. US authorities may have access to your data without you having an adequate possibility of legal protection. Unsubscribing from the newsletter is possible at any time. You will find the information on our data protection policy here.

Karrierewege nach dem Master-Studium Medical and Pharmaceutical Biotechnology

Als Absolventin oder Absolvent des Master-Studiengangs Medical and Pharmaceutical Biotechnology werden Sie hauptsächlich in pharmazeutischen und biotechnologischen Unternehmen und als Mitarbeiterin oder Mitarbeiter in medizinischen Forschungseinrichtungen tätig sein.

Nach dem Studium können Sie sich außerdem für ein PhD-Studium an einer Universität im In- oder Ausland entscheiden. PhD-Kooperationsverträge liegen mit der Donau-Universität Krems und der Veterinärmedizinischen Universität Wien vor. Diese Verträge stellen einen geregelten Eintritt in das PhD-Programm der jeweiligen Universität sicher.

Mögliche Arbeitsfelder
F&E-Tätigkeiten im akademischen Bereich und in der Industrie
Klinische Studien und Zulassung von Wirkstoffen
Planung und Steuerung von biotechnologischen Prozessen (Fermentation)
Biomedizinische und analytische Testverfahren
Koordinative Tätigkeiten in Produktion, Qualitätskontrolle, Qualitätssicherung und Zulassung
Marketing und Vertrieb
Medizintechnik
Lebensmitteltechnologie & Lebensmitteluntersuchung
Industrielle und Umweltbiotechnologie

10 Gründe

Es gibt viele Gründe, warum wir auf unsere Hochschule stolz sind. Finden Sie heraus, was uns besonders macht.

Mehr erfahren

Studierenden-Stadt Krems

Was Krems besonders lebenswert macht? Lernen Sie Krems als Studierenden-Stadt kennen.

Mehr erfahren

Service-Stellen

Von Studiumsorganisation bis Praktikums- und Berufsberatung. Informieren Sie sich über das Plus an Services.

Mehr erfahren

Studienberatung

Brauchen Sie Hilfe bei der Entscheidung fürs Studium? Unsere Studienberatung berät Sie gerne in einem persönlichen Gespräch.

Mehr erfahren

Im Fokus: Medical and Pharmaceutical Biotechnology

Klicken Sie sich durch die Videos zum Studiengang.

Lernen Sie unsere Fachhochschule von einer ganz neuen und persönlichen Seite virtuell kennen.

Zur Plattform Virtual IMC

Info-Veranstaltungen

Virtual Master Talks
Mittwoch
05.07.2023
17:00 - 20:00
Virtual Master Talks
Holen Sie sich alle Informationen zu unseren wirtschaftswissenschaftlichen Master-Studiengängen bequem von zu Hause aus. Unsere...
OnlineOnline
Open House 2024
Samstag
17.02.2024
09:00 - 15:00
Open House 2024
Erhalten Sie den perfekten Einblick in den Studienalltag an der IMC FH Krems und sprechen Sie mit Studierenden und Studiengangsleitungen!
IMC Campus KremsIMC Campus Krems

Alle Events anzeigen

Unser Team

Lernen Sie das Kern-Team des Master-Studiengangs Medical and Pharmaceutical Biotechnology kennen.

Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger
Institutsleitung Biotechnologie / Studiengangsleitung Medical and Pharmaceutical Biotechnology
Institut Biotechnologie
+43 2732 802 521
[email protected]
IMC Campus KremsIMC Campus Trakt G
Heterologe Experssion von Proteinen, Zellkultursysteme, Zellkulturmodelle, Peptidengineering
Produktentwicklung in der Life Science Branche, Projektleitung und Projektmanagement
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Immobilisierung von Kameloidantikörper für therapeutische Apherese und für die Unterstützung von Dialyse
Projektleitung, Department of Science & Technology
Extrazelluläre Vesikel aus dem Hoffa-Fettkörper - ein neuer Ansatz der Knorpelregeneration?
Department of Science & Technology
Testung von rekombinanten polyklonalen Antikörperfragmenten gegen Gluten-Peptide
Projektleitung, Department of Science & Technology
Die Rolle von NFR2 in der Melanomprogression - Einblicke in die Mechanismen von Metastasen
Projektleitung, Department of Science & Technology
Etablierung der molekularen Toxikologie für rasche, frühzeitige sowie sensitive Toxizitätsbestimmungen und Biokompatibilität
Projektleitung, Department of Science & Technology
Entwicklung einer Design-Pipeline für innovative Protein-Protein-Interaktionshemmer
Department of Science & Technology
MEMESA – Metastasierendes Melanom Spezifische Antikörper
Projektleitung, Department of Science & Technology
AdsorbTech: Entwicklung einer neuen Technologieplattform für Peptid-basierte therapeutische Apheresesysteme
Projektleitung, Department of Science & Technology
Entwicklung neuer immunregulierender Peptide und geschlechtsspezifischer organotypischer Zellmodelle für humane Sepsis
Department of Science & Technology
Entwicklung neuer Methoden zur Verbesserung von immuntherapeutischen Verfahren in der Onkologie
Department of Science & Technology
Funktionale Validierung prädiktiver Biomarker für zielgerichtete Krebstherapien
Department of Science & Technology
Etablierung innovativer, vaskulärer Äquivalente zur Entwicklung von Detektionsmodulen für Hochdurchsatz-Verfahren und zur Entwicklung von anti-entzündlichen Peptiden
Projektleitung, Department of Science & Technology
Etablierung innovativer humaner Tumor-Mimetika für das Screening von bioaktiven Wirkstoffen
Department of Science & Technology
Biopharm - Isolation bioaktiver Stoffe aus Cyanobakterien
Projektleitung, Department of Science & Technology
Zellbasierte Testsysteme für bioaktive Substanzen
Projektleitung, Department of Science & Technology
Stierschneider, A., Neuditschko, B., Colleselli, K., Hundsberger, H., Herzog, F., & Wiesner, C. (2023): Comparative and Temporal Characterization of LPS and Blue-Light-Induced TLR4 Signal Transduction and Gene Expression in Optogenetically Manipulated Endothelial Cells. Cells, 12(697).
Doi: https://doi.org/10.3390/cells12050697
Lucas, R., Hadizamani, Y., Enkhbaatar, P., Csanyi, G., Caldwell, R. W., Hundsberger, H., Sridhar, S., Lever, A. A., Hudel, M., Ash, D., Ushio-Fukai, M., Fukai, T., Chakraborty, T., Verin, A., Eaton, D. C., Romero, M., & Hamacher, J. (2022): Dichotomous Role of Tumor Necrosis Factor in Pulmonary Barrier Function and Alveolar Fluid Clearance. Frontiers in Physiology, 12: 793251.
Doi: https://doi.org/10.3389/fphys.2021.793251
Weitzenböck, HP., Gschwendtner, A., Wiesner, C., Depke, M., Schmidt, F., Trautinger, F., Hengstschläger, M., Hundsberger, H., Mikula, M. (2022): Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment. Cancer Medicine, 11(4): 956-967.
Doi: https://doi.org/10.1002/cam4.4506
Stierschneider, A., Grünstäudl, P., Colleselli, K., Atzler, J., Klein, C., Hundsberger, H., Wiesner, C. (2021): Light-Inducible Spatio-Temporal Control of TLR4 and NF-κB-Gluc Reporter in Human Pancreatic Cell Line. International Journal of Molecular Sciences, 22(17): 9232.
Doi: https://doi.org/10.3390/ijms22179232
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Kinslechner, K., Schütz, B., Pistek, M., Rapolter, P., Weitzenböck, H. P., Hundsberger, H., Mikulits, W., Grillari, J., Röhrl, C., Hengstschläger, M., Stangl, H., & Mikula, M. (2019): Loss of SR-BI Down-Regulates MITF and Suppresses Extracellular Vesicle Release in Human Melanoma. International journal of molecular sciences, 20(5): 1063.
Doi: https://doi.org/10.3390/ijms20051063
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475
Hundsberger, H., Önder, K., Schuller-Götzburg, P., Virok, D. P., Herzog, J., & Rid, R. (2017): Assembly and use of high-density recombinant peptide chips for large-scale ligand screening is a practical alternative to synthetic peptide libraries. BMC genomics, 18(1): 450.
Doi: https://doi.org/10.1186/s12864-017-3814-3
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Volk, K., Breunig, S. D., Rid, R., Herzog, J., Bräuer, M., Hundsberger, H., Klein, C., Müller, N., & Önder, K. (2017): Structural analysis and interaction studies of acyl-carrier protein (acpP) of Staphylococcus aureus, an extraordinarily thermally stable protein. Biological chemistry, 398(1): 125-133.
Doi: https://doi.org/10.1515/hsz-2016-0185
Schütz, B., Koppensteiner, A., Schörghofer, D., Kinslechner, K., Timelthaler, G., Eferl, R., Hengstschläger, M., Missbichler, A., Hundsberger, H., & Mikula, M. (2016): Generation of metastatic melanoma specific antibodies by affinity purification. Scientific reports, 6: 37253.
Doi: https://doi.org/10.1038/srep37253
Al-Harthy, T., Zoghaib, W. M., Pflüger, M., Schöpel, M., Önder, K., Reitsammer, M., Hundsberger, H., Stoll, R., & Abdel-Jalil, R. (2016): Design, Synthesis, and Cytotoxicity of 5-Fluoro-2-methyl-6-(4-aryl-piperazin-1-yl) Benzoxazoles. Molecules, 21(10): 1290.
Doi: https://doi.org/10.3390/molecules21101290
Al-Harthy, T., Abdel-Jalil, R., Zoghaib, W., Pflüger, M., Hofmann, E., & Hundsberger, H. (2016): Design and synthesis of benzothiazole schiff bases of potential antitumor activity. Heterocycles, 92(7): 1282-1292.
Doi: https://doi.org/10.3987/COM-16-13471
Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7
Jacobi, N., Smolinska, V., Stierschneider, A., Klein, C., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2016): Development of organotypic cancer models for the identification of individualized cancer therapies. In FH des BFI Wien (Hrsg.), Online-Tagungsband FHK Forschungsforum 2016. Wien: FFH.
Herzog, J., Rid, R., Wagner, M., Hundsberger, H., Eger, A., Bauer, J., & Önder, K. (2015): Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways. BMC research notes, 8: 785.
Doi: https://doi.org/10.1186/s13104-015-1783-7
Kreiseder, B., Holper-Schichl, Y. M., Muellauer, B., Jacobi, N., Pretsch, A., Schmid, J. A., de Martin, R., Hundsberger, H., Eger, A., & Wiesner, C. (2015): Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PloS one, 10(3): e0119402.
Doi: https://doi.org/10.1371/journal.pone.0119402
Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P., & Wiesner, C. (2014): Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PloS one, 9(6): e97929.
Doi: https://doi.org/10.1371/journal.pone.0097929
Rid, R., Hundsberger, H., & Onder, K. (2014): Compound screening and transcriptional profiling in human primary keratinocytes: a brief guideline. Methods in molecular biology, 1195: 99-109.
Doi: https://doi.org/10.1007/7651_2013_50
Kapuścik, A., Hrouzek, P., Kuzma, M., Bártová, S., Novák, P., Jokela, J., Pflüger, M., Eger, A., Hundsberger, H., Kopecký, J. (2013): Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent. Chembiochem : a European journal of chemical biology, 14(17): 2329-2337.
Doi: https://doi.org/10.1002/cbic.201300246
Rid, R., Herzog, J., Maier, R. H., Hundsberger, H., Eger, A., Hintner, H., Bauer, J. W., Onder, K. (2013): Real-time monitoring of relative peptide-protein interaction strengths in the yeast two-hybrid system. Assay and drug development technologies, 11(4): 269-275.
Doi: https://doi.org/10.1089/adt.2012.496
Rid, R., Wagner, M., Maier, C. J., Hundsberger, H., Hintner, H., Bauer, J. W., & Onder, K. (2013): Deciphering the calcitriol-induced transcriptomic response in keratinocytes: presentation of novel target genes. Journal of molecular endocrinology, 50(2): 131–149.
Doi: https://doi.org/10.1530/JME-11-0191
Kreiseder, B., Orel, L., Bujnow, C., Buschek, S., Pflueger, M., Schuett, W., Hundsberger, H., de Martin, R., Wiesner, C. (2013): α‐Catulin downregulates E‐cadherin and promotes melanoma progression and invasion. International journal of cancer, 132(3): 521-530.
Doi: https://doi.org/10.1002/ijc.27698
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
Khare, V., Lyakhovich, A., Dammann, K., Lang, M., Borgmann, M., Tichy, B., Pospisilova, S., Luciani, G., Campregher, C., Evstatiev, R., Pflueger, M., Hundsberger, H., & Gasche, C. (2013): Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochemical Pharmacology, 85(2): 234-244.
Doi: https://doi.org/10.1016/j.bcp.2012.10.026
Maier, C., Maier, R., Rid, R., Trost, A., Hundsberger, H., Eger, A., Hintner, H., Bauer, J., Onder, K. (2012): PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1,25-(OH)2D3 signaling. BMC molecular biology, 13: 18.
Doi: https://doi.org/10.1186/1471-2199-13-18
Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., Wiesner, C. (2011): CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. British journal of cancer, 104(3): 469-479.
Doi: https://doi.org/10.1038/sj.bjc.6606056
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D., Wendel, A., Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in Bioscience, 13: 5374-86.
Doi: https://doi.org/10.2741/3087
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D. N., Wendel, A., & Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in bioscience : a journal and virtual library, 13: 5374–5386.
Doi: https://doi.org/10.2741/3087
Wiesner, C., Pflueger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schuett, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene interdisziplinar, 3(1).
Wiesner, C., Pflüger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schütt, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene Interdisziplinär, 3(1): Doc05.
Wiesner, C., Lucas, R., Pflueger, M., Kleber, C., Kopecky, J., Stys, D., Entler, B., Hundsberger, H., Atzler, J., Hrouzek, P., Lukesova, A., Schuett, W., (2007): Endothelial Cell-Based Methods for the Detection of Cyanobacterial Anti- Inflammatory and Wound-Healing Promoting Metabolites. Drug Metabolism Letters, 1(4): 254-260.
Doi: https://doi.org/10.2174/187231207783221385
Lucas, R., Hundsberger, H., Pflueger, M., Fischer, B., Morel, D., Braun, C., Wendel, A., Chakraborty, T., Schuett, W., Wiesner, C., Hamacher, J. (2007): The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug. Letters in Drug Design & Discovery, 4(5): 336-340.
Doi: https://doi.org/10.2174%2F157018007780867816
Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger
Institutsleitung Biotechnologie / Studiengangsleitung Medical and Pharmaceutical Biotechnology
Institutsleitung Biotechnologie / Studiengangsleitung Medical and Pharmaceutical Biotechnology
Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger
Kernkompetenzen
- Heterologe Experssion von Proteinen, Zellkultursysteme, Zellkulturmodelle, Peptidengineering
- Produktentwicklung in der Life Science Branche, Projektleitung und Projektmanagement

DI (FH) Anita Koppensteiner
Scientist Institut Applied Chemistry
Institut Applied Chemistry
+43 2732 802 527
[email protected]
IMC Campus KremsIMC Campus Trakt D
Protein Produktion, Aufreinigung und Analyse
Zellbasierte Testsysteme/Mikroskopie
Biochemische Testmethoden und Analysen
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Applied Chemistry
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Theraferm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Die Rolle von NFR2 in der Melanomprogression - Einblicke in die Mechanismen von Metastasen
Department of Science & Technology
Extremophiles
Department of Science & Technology
MEMESA – Metastasierendes Melanom Spezifische Antikörper
Department of Science & Technology
AdsorbTech: Entwicklung einer neuen Technologieplattform für Peptid-basierte therapeutische Apheresesysteme
Department of Science & Technology
Etablierung innovativer, vaskulärer Äquivalente zur Entwicklung von Detektionsmodulen für Hochdurchsatz-Verfahren und zur Entwicklung von anti-entzündlichen Peptiden
Department of Science & Technology
Rassy, W., Ripper, D., Pomare, E., Winkler, S., Koppensteiner, A., Spadiut O.,Schild, D. (2023): Incorporation of ionic rare earth elements as a form of microbial environmental remediation. Frontiers in Environmental Science, 11(Section Toxicology, Pollution and the Environment).
Doi: https://doi.org/10.3389/fenvs.2023.1112612
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Schütz, B., Koppensteiner, A., Schörghofer, D., Kinslechner, K., Timelthaler, G., Eferl, R., Hengstschläger, M., Missbichler, A., Hundsberger, H., & Mikula, M. (2016): Generation of metastatic melanoma specific antibodies by affinity purification. Scientific reports, 6: 37253.
Doi: https://doi.org/10.1038/srep37253
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
DI (FH) Anita Koppensteiner
Scientist Institut Applied Chemistry
Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger
Institutsleitung Institute Krems Bioanalytics / Professor Department of Science and Technology
Institute Krems Bioanalytics
+43 2732 802 369
[email protected]
IMC TFZIMC TFZ Haupthaus (Verwaltungsgebäude 1)
Wirkstoffentwicklung
Organotypische Krankheitsmodelle
Bioanalytik und Biomarker
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Stoffwechsel-Plasma-Analyse bei metabolischem Syndrom und Tumorkachexie
Projektleitung, Department of Science & Technology
DNA Methylierung im Lungenkrebs und ihre geschlechtsspezifische Auswirkung auf die Effizienz epigenetischer Therapien
Department of Science & Technology
Entwicklung von therapeutischen Peptiden für Krebs- und regenerative Medizin
Projektleitung, Department of Science & Technology
Etablierung der molekularen Toxikologie für rasche, frühzeitige sowie sensitive Toxizitätsbestimmungen und Biokompatibilität
Department of Science & Technology
Entwicklung komplexer extrakorporaler Karzinommodelle für die Identifikation personalisierter Krebstherapien
Projektleitung, Department of Science & Technology
AdsorbTech: Entwicklung einer neuen Technologieplattform für Peptid-basierte therapeutische Apheresesysteme
Department of Science & Technology
Entwicklung neuer immunregulierender Peptide und geschlechtsspezifischer organotypischer Zellmodelle für humane Sepsis
Department of Science & Technology
Entwicklung neuer Methoden zur Verbesserung von immuntherapeutischen Verfahren in der Onkologie
Projektleitung, Department of Science & Technology
Funktionale Validierung prädiktiver Biomarker für zielgerichtete Krebstherapien
Projektleitung, Department of Science & Technology
Etablierung innovativer humaner Tumor-Mimetika für das Screening von bioaktiven Wirkstoffen
Projektleitung, Department of Science & Technology
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017): ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 9(4): 33.
Doi: https://doi.org/10.3390/cancers9040033
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7
Jacobi, N., Smolinska, V., Stierschneider, A., Klein, C., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2016): Development of organotypic cancer models for the identification of individualized cancer therapies. In FH des BFI Wien (Hrsg.), Online-Tagungsband FHK Forschungsforum 2016. Wien: FFH.
Herzog, J., Rid, R., Wagner, M., Hundsberger, H., Eger, A., Bauer, J., & Önder, K. (2015): Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways. BMC research notes, 8: 785.
Doi: https://doi.org/10.1186/s13104-015-1783-7
Kreiseder, B., Holper-Schichl, Y. M., Muellauer, B., Jacobi, N., Pretsch, A., Schmid, J. A., de Martin, R., Hundsberger, H., Eger, A., & Wiesner, C. (2015): Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PloS one, 10(3): e0119402.
Doi: https://doi.org/10.1371/journal.pone.0119402
Bakiri, L., Macho-Maschler, S., Custic, I., Niemiec, J., Guío-Carrión, A., Hasenfuss, S. C., Eger, A., Müller, M., Beug, H., & Wagner, E. F. (2015): Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression. Cell death and differentiation, 22(2): 336–350.
Doi: https://doi.org/10.1038/cdd.2014.157
Spilka, R., Ernst, C., Bergler, H., Rainer, J., Flechsig, S., Vogetseder, A., Lederer, E., Benesch, M., Brunner, A., Geley, S., Eger, A., Bachmann, F., Doppler, W., Obrist, P., & Haybaeck, J. (2014): eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cellular oncology (Dordrecht), 37(4): 253–267.
Doi: https://doi.org/10.1007/s13402-014-0181-9
Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P., & Wiesner, C. (2014): Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PloS one, 9(6): e97929.
Doi: https://doi.org/10.1371/journal.pone.0097929
Kapuścik, A., Hrouzek, P., Kuzma, M., Bártová, S., Novák, P., Jokela, J., Pflüger, M., Eger, A., Hundsberger, H., Kopecký, J. (2013): Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent. Chembiochem : a European journal of chemical biology, 14(17): 2329-2337.
Doi: https://doi.org/10.1002/cbic.201300246
Rid, R., Herzog, J., Maier, R. H., Hundsberger, H., Eger, A., Hintner, H., Bauer, J. W., Onder, K. (2013): Real-time monitoring of relative peptide-protein interaction strengths in the yeast two-hybrid system. Assay and drug development technologies, 11(4): 269-275.
Doi: https://doi.org/10.1089/adt.2012.496
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
Imhof, M., Karas, I., Gomez, I., Eger, A., & Imhof, M. (2013): Interaction of tumor cells with the immune system: implications for dendritic cell therapy and cancer progression. Drug discovery today, 18(1-2): 35-42.
Doi: https://doi.org/10.1016/j.drudis.2012.07.010
Maier, C., Maier, R., Rid, R., Trost, A., Hundsberger, H., Eger, A., Hintner, H., Bauer, J., Onder, K. (2012): PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1,25-(OH)2D3 signaling. BMC molecular biology, 13: 18.
Doi: https://doi.org/10.1186/1471-2199-13-18
Vonach, C., Viola, K., Giessrigl, B., Huttary, N., Raab, I., Kalt, R., Krieger, S., Vo, T. P., Madlener, S., Bauer, S., Marian, B., Hämmerle, M., Kretschy, N., Teichmann, M., Hantusch, B., Stary, S., Unger, C., Seelinger, M., Eger, A., Mader, R., Jäger, W., Schmidt, W., Grusch, M., Dolznig, H., Mikulits, W., Krupitza, G. (2011): NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. British journal of cancer, 105(2): 263-271.
Doi: https://doi.org/10.1038/bjc.2011.194
Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., Wiesner, C. (2011): CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. British journal of cancer, 104(3): 469-479.
Doi: https://doi.org/10.1038/sj.bjc.6606056
Spaderna, S., Schmalhofer, O., Wahlbuhl, M., Dimmler, A., Bauer, K., Sultan, A., Hlubek, F., Jung, A., Strand, D., Eger, A., Kirchner, T., Behrens, J., & Brabletz, T. (2008): The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer research, 68(2): 537–544.
Doi: https://doi.org/10.1158/0008-5472.CAN-07-5682
Mikula M., Lahsnig C., Fischer A. N. M., Proell V., Huber H, Fuchs E., Eger A., Beug H. and Mikulits W. (2007): Epithelial plasticity of hepatocytes during liver tumor progression. Stem cells and their potential for clinical application. NATO Science for Peace and Security. Series/NATO Science Foundation. Springer Netherland, Edition 1.
Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., Brabletz, T., Strand, D., Obrist, P., Sommergruber, W., Schweifer, N., Wernitznig, A., Beug, H., Foisner, R., & Eger, A. (2007): The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene, 26(49): 6979–6988.
Doi: https://doi.org/10.1038/sj.onc.1210508
Aigner, K., Descovich, L., Mikula, M., Sultan, A., Dampier, B., Bonné, S., van Roy, F., Mikulits, W., Schreiber, M., Brabletz, T., Sommergruber, W., Schweifer, N., Wernitznig, A., Beug, H., Foisner, R., & Eger, A. (2007): The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS letters, 581(8): 1617-24.
Doi: https://doi.org/10.1016/j.febslet.2007.03.026
Pacher, M., Seewald, M. J., Mikula, M., Oehler, S., Mogg, M., Vinatzer, U., Eger, A., Schweifer, N., Varecka, R., Sommergruber, W., Mikulits, W., & Schreiber, M. (2007): Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis, 28(1): 49-59.
Doi: https://doi.org/10.1093/carcin/bgl091
Spaderna, S., Schmalhofer, O., Hlubek, F., Berx, G., Eger, A., Merkel, S., Jung, A., Kirchner, T., & Brabletz, T. (2006): A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology, 131(3): 830–840.
Doi: https://doi.org/10.1053/j.gastro.2006.06.016
Stary, M., Pasteiner, W., Summer, A., Hrdina, A., Eger, A., & Weitzer, G. (2005): Parietal endoderm secreted SPARC promotes early cardiomyogenesis in vitro. Experimental cell research, 310(2): 331-43.
Doi: https://doi.org/10.1016/j.yexcr.2005.07.013
Eger, A., Mikulits, W. (2005): Models of Epithelial to Mesenchymal Transition. Drug Discovery Today: Disease Models, 2(1): 57-63.
Doi: https://doi.org/10.1016/j.ddmod.2005.04.001
Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005): DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene, 24(14): 2375-85.
Doi: https://doi.org/10.1038/sj.onc.1208429
Eger, A., Stockinger, A., Park, J., Langkopf, E., Mikula, M., Gotzmann, J., Mikulits, W., Beug, H., & Foisner, R. (2004): β-catenin and TGFβ signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene, 23(15): 2672-2680.
Doi: https://doi.org/10.1038/sj.onc.1207416
Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., & Mikulits, W. (2004): Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutation research, 566(1): 9–20.
Doi: https://doi.org/10.1016/s1383-5742(03)00033-4
Stockinger, A., Eger, A., Wolf, J., Beug, H., & Foisner, R. (2001): E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. The Journal of cell biology, 154(6): 1185–1196.
Doi: https://doi.org/10.1083/jcb.200104036
Eger A. and Foisner R. (2000): Dynamic and cross talk of junctional proteins: a molecular basis for the regulation of cell adhesion and epithelial polarity. Protoplasma, 211(3-4): 125-133.
Eger, A., Stockinger, A., Schaffhauser, B., Beug, H., & Foisner, R. (2000): Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. The Journal of cell biology, 148(1): 173-188.
Doi: https://doi.org/10.1083/jcb.148.1.173
Gotzmann, J., Eger, A., Meissner, M., Grimm, R., Gerner, C., Sauermann, G., & Foisner, R. (1997): Two-dimensional electrophoresis reveals a nuclear matrix-associated nucleolin complex of basic isoelectric point. Electrophoresis, 18(14): 2645–2653.
Doi: https://doi.org/10.1002/elps.1150181421
Eger, A., Stockinger, A., Wiche, G., & Foisner, R. (1997): Polarisation-dependent association of plectin with desmoplakin and the lateral submembrane skeleton in MDCK cells. Journal of cell science, 110: 1307-1316.
Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger
Institutsleitung Institute Krems Bioanalytics / Professor Department...
Prof.(FH) Mag. Dr. Christoph Wiesner
Fachhochschulprofessor Institut Biotechnologie
Institut Biotechnologie
+43 2732 802 276
[email protected]
IMC Campus KremsIMC Campus Trakt G
Zell- und Molekularbiologie
Wirkstoff Screening
Projekt management
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
EvoFerm
Department of Science & Technology
Spike-Fermentation
Department of Science & Technology
Entwicklung einer optogenetisch kontrollierbaren MSC-Zelllinie für die präzise Regulation immunmodulatorischer Faktoren
Projektleitung, Department of Science & Technology
Biomarker-basierte therapeutische Prävention von Knochenmetastasen beim Mammakarzinom: die phathophysiologische Rolle der endostalen Nische
Projektleitung, Department of Science & Technology
Entwicklung leistungsfähiger Diagnostikverfahren und neuer Therapieansätze in Inflammation und Sepsis
Projektleitung, Department of Science & Technology
Theraferm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Testung von rekombinanten polyklonalen Antikörperfragmenten gegen Gluten-Peptide
Department of Science & Technology
Zellbasierte Testsysteme für bioaktive Substanzen
Department of Science & Technology
Stierschneider, A., Neuditschko, B., Colleselli, K., Hundsberger, H., Herzog, F., & Wiesner, C. (2023): Comparative and Temporal Characterization of LPS and Blue-Light-Induced TLR4 Signal Transduction and Gene Expression in Optogenetically Manipulated Endothelial Cells. Cells, 12(697).
Doi: https://doi.org/10.3390/cells12050697
Weitzenböck, HP., Gschwendtner, A., Wiesner, C., Depke, M., Schmidt, F., Trautinger, F., Hengstschläger, M., Hundsberger, H., Mikula, M. (2022): Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment. Cancer Medicine, 11(4): 956-967.
Doi: https://doi.org/10.1002/cam4.4506
Stierschneider, A., Grünstäudl, P., Colleselli, K., Atzler, J., Klein, C., Hundsberger, H., Wiesner, C. (2021): Light-Inducible Spatio-Temporal Control of TLR4 and NF-κB-Gluc Reporter in Human Pancreatic Cell Line. International Journal of Molecular Sciences, 22(17): 9232.
Doi: https://doi.org/10.3390/ijms22179232
Pretsch, A., Nagl, M., Wiesner, C., Hollaus, R., Genov, M. (2021): Polyguanidine polymers and methods of use thereof (US11013760B2). United States Patent Office.
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Sarne, V., Huter, S., Braunmueller, S., Rakob, L., Jacobi, N., Kitzwögerer, M., Wiesner, C., Obrist, P., & Seeboeck, R. (2020): Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines. International journal of molecular sciences, 21(13): 4595.
Doi: https://doi.org/10.3390/ijms21134595
Pretsch, A., Nagl, M., Wiesner, C., Hollaus, R., Genov, M. (2019): Method for producing polyguanidines (US10335431B2). United States Patent Office.
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Pretsch, A., Nagl, M., Wiesner, C., Burgmann, H. (2017): Bioactive polymers (US9567294B2). United States Patent Office.
Genov, M., Kreiseder, B., Nagl, M., Wiesner, C. et al. (2016): Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB. Journal of Cancer, 7(5): 555.
Doi: https://doi:10.7150/jca.13614
Preisitsch, M., Niedermeyer, T., Heiden, SE., Neidhardt, I., Kumpfmueller, J., Wurster, M., Harmrolfs, K., Wiesner, C., Enke, H., Mueller, R., Mundt, S. (2016): Cylindrofridins A–C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. Journal of natural products, 79(1): 106-115.
Doi: https://doi.org/10.1021/acs.jnatprod.5b00768
Preisitsch, M., Heiden, SE., Beerbaum, M., Niedermeyer, T., Schneefeld, M., Herrmann, J., Kumpfmueller, J., Thuermer, A., Neidhardt, I., Wiesner, C., Daniel, R., Mueller, R., Bange, FC., Schmieder, P., Schweder, T., Mundt, S. (2016): Effects of halide ions on the carbamidocyclophane biosynthesis in Nostoc sp. CAVN2. Marine drugs, 14(1): 21.
Doi: https://doi.org/10.3390/md14010021
Preisitsch, M., Harmrolfs, K., Pham, HT., Heidern, SE., Fuessl, A., Wiesner, C., Pretsch, A., Switecka-Hagenbruch, M., Niedermeyer, TH., Mueller, R., Mundt, S. (2015): Anti-MRSA-acting carbamidocyclophanes H-L from the Vietnamese cyanobacterium Nostoc sp. CAVN2. The Journal of antibiotics, 68(9): 600-600.
Doi: https://doi.org/10.1038/ja.2015.79
Kreiseder, B., Holper-Schichl, Y. M., Muellauer, B., Jacobi, N., Pretsch, A., Schmid, J. A., de Martin, R., Hundsberger, H., Eger, A., & Wiesner, C. (2015): Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PloS one, 10(3): e0119402.
Doi: https://doi.org/10.1371/journal.pone.0119402
Preisitsch, M., Harmrolfs, K., Pham, H., Heiden, SE., Fuessel, A., Wiesner, C., Pretsch, A., et al. (2015): Anti-MRSA-acting carbamidocyclophanes H–L from the Vietnamese cyanobacterium Nostoc sp. CAVN2. The Journal of antibiotics, 68(3): 165-177.
Doi: https://doi.org/10.1038/ja.2014.118
Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P., & Wiesner, C. (2014): Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PloS one, 9(6): e97929.
Doi: https://doi.org/10.1371/journal.pone.0097929
Kreiseder, B., Orel, L., Bujnow, C., Buschek, S., Pflueger, M., Schuett, W., Hundsberger, H., de Martin, R., Wiesner, C. (2013): α‐Catulin downregulates E‐cadherin and promotes melanoma progression and invasion. International journal of cancer, 132(3): 521-530.
Doi: https://doi.org/10.1002/ijc.27698
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., Wiesner, C. (2011): CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. British journal of cancer, 104(3): 469-479.
Doi: https://doi.org/10.1038/sj.bjc.6606056
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D., Wendel, A., Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in Bioscience, 13: 5374-86.
Doi: https://doi.org/10.2741/3087
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D. N., Wendel, A., & Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in bioscience : a journal and virtual library, 13: 5374–5386.
Doi: https://doi.org/10.2741/3087
Wiesner, C., Pflueger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schuett, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene interdisziplinar, 3(1).
Wiesner, C., Pflüger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schütt, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene Interdisziplinär, 3(1): Doc05.
Wiesner, C., Winsauer, G., Resch, U. et al. (2008): α-Catulin, a Rho signalling component, can regulate NF-κB through binding to IKK-β, and confers resistance to apoptosis. Oncogene , 27: 2159–2169.
Doi: https://doi.org/10.1038/sj.onc.1210863
Wiesner, C., Lucas, R., Pflueger, M., Kleber, C., Kopecky, J., Stys, D., Entler, B., Hundsberger, H., Atzler, J., Hrouzek, P., Lukesova, A., Schuett, W., (2007): Endothelial Cell-Based Methods for the Detection of Cyanobacterial Anti- Inflammatory and Wound-Healing Promoting Metabolites. Drug Metabolism Letters, 1(4): 254-260.
Doi: https://doi.org/10.2174/187231207783221385
Winter, D., Moser, J., Kriehuber, E., Wiesner, C., Knobler, R., Trautinger, F., Bombosi, P., Stingl, G., Petzelbauer, P., Rot, A., & Maurer, D. (2007): Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. Journal of immunology, 179(6): 4272-4282.
Doi: https://doi.org/10.4049/jimmunol.179.6.4272
Lucas, R., Hundsberger, H., Pflueger, M., Fischer, B., Morel, D., Braun, C., Wendel, A., Chakraborty, T., Schuett, W., Wiesner, C., Hamacher, J. (2007): The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug. Letters in Drug Design & Discovery, 4(5): 336-340.
Doi: https://doi.org/10.2174%2F157018007780867816
Hofer-Warbinek, R., Schmid, J.A., Mayer, H., Winsauer, G., Orel, L., Mueller, B., Wiesner, C., Binder, B.R., de Martin, R. (2004): A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53. Cell Death & Differentiation, 11(12): 1317 - 1325.
Doi: https://doi.org/10.1038%2Fsj.cdd.4401502
Wiesner, C., Hoeth, M., De Martin, R. (2003): Functional screening for transcription factors (US20030059858A1). United States Patent Office.
Wiesner, C., Hoeth, M., Binder, B.R., de Martin, R. (2002): A functional screening assay for the isolation of transcription factors. Nucleic Acids Research, 30(16): e80.
Doi: https://doi.org/10.1093/nar/gnf079
Prof.(FH) Mag. Dr. Christoph Wiesner
Fachhochschulprofessor Institut Biotechnologie
Prof.(FH) DI Dominik Schild
Fachhochschulprofessor Institut Biotechnologie
Institut Biotechnologie
+43 2732 802 501
[email protected]
IMC Campus KremsIMC Campus Trakt G
Fermentationsentwicklung
Biochemische Verfahrenstechnik
Prozessingenieur
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Applied Chemistry
Bachelor of Science in Engineering / Vollzeit
EvoFerm
Projektleitung, Department of Science & Technology
Spike-Fermentation
Projektleitung, Department of Science & Technology
Theraferm
Projektleitung, Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Projektleitung, Department of Science & Technology
Synthese und industrielle Verwendung von Hydroxytyrosol
Projektleitung, Department of Science & Technology
Extremophiles
Department of Science & Technology
Co-Kultivierung von Mikroorganismen
Projektleitung, Department of Science & Technology
Zellbasierte Testsysteme für bioaktive Substanzen
Department of Science & Technology
Rassy, W., Ripper, D., Pomare, E., Winkler, S., Koppensteiner, A., Spadiut O.,Schild, D. (2023): Incorporation of ionic rare earth elements as a form of microbial environmental remediation. Frontiers in Environmental Science, 11(Section Toxicology, Pollution and the Environment).
Doi: https://doi.org/10.3389/fenvs.2023.1112612
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Amer, H., Mimini, V., Schild, D., Rinner, U., Bacher, H., Potthast, A., Rosenau, T. (2019): Gram-scale economical synthesis of trans-coniferyl alcohol and its corresponding thiol. Holzforschung, 74(2): 197-202.
Doi: https://doi.org/10.1515/hf-2018-0297
Prof.(FH) DI Dominik Schild
Fachhochschulprofessor Institut Biotechnologie
Prof.(FH) Mag. Dana Mezricky
Fachhochschulprofessorin Institut Biotechnologie
Institut Biotechnologie
+43 2732 802 322
[email protected]
IMC Campus KremsIMC Campus Trakt G
GMP/GLP
Molekulare Biologie
Proteinchemie / Immunologie / Biochemische Alalysemethoden
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Applied Chemistry
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
EvoFerm
Department of Science & Technology
Spike-Fermentation
Department of Science & Technology
Theraferm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Extremophiles
Department of Science & Technology
Co-Kultivierung von Mikroorganismen
Department of Science & Technology
Nahlik,V., Cizkova,M., Singh,A., Mezricky,D., Rucki,M., Andresen,E., Vitova,M. (2022): Growth of the Red Alga Galdieria suphuraria in Re Mud-Containing Medium and Accumulation of Rare Earth Elements. Springer Nature: Waste and Biomass Valorization , 13(12, Dezember 2022): -.
Doi: https://doi.org/10.1007/s12649-022-02021-3
Náhlík, V., Zachleder, V., Čížková, M., Bišová, K., Singh, A., Mezricky, D., Řezanka, T., Vítová, M. (2021): Growth under Different Trophic Regimes and Synchronization of the Red Microalga Galdieria sulphuraria. Biomolecules, 11(7)(939).
Čížková, M., Mezricky, P., Mezricky, D., Rucki, M., Zachleder, V., Vítová, M. (2020): Bioaccumulation of Rare Earth Elements from Waste Luminophores in the Red Algae, Galdieria phlegrea. Waste Biomass Valor.
Doi: https://doi.org/10.1007/s12649-020-01182-3
Rezanka, T., Rezanka, M., Mezricky, D., Vítova, M. (2020): Lipidomic analysis of diatoms cultivated with silica nanoparticles. Phytochemistry, 177: 112452.
Doi: https://doi.org/10.1016/j.phytochem.2020.112452
Čížková, M., Mezricky, D., Rucki, M., Tóth, T. M., Náhlík, V., Lanta, V., Bišová, K., Zachleder, V., & Vítová, M. (2019): Bio-mining of Lanthanides from Red Mud by Green Microalgae. Molecules , 24(7): 1356.
Doi: https://doi.org/10.3390/molecules24071356
Řezanka, T., Kaineder, K., Mezricky, D., Řezanka, M., Bišová, K., Zachleder, V., & Vítová, M. (2016): The effect of lanthanides on photosynthesis, growth, and chlorophyll profile of the green alga Desmodesmus quadricauda. Photosynthesis Research, 130(1-3): 335-346.
Doi: https://doi.org/10.1007/s11120-016-0263-9
Prof.(FH) Mag. Dana Mezricky
Fachhochschulprofessorin Institut Biotechnologie
Prof.(FH) Priv.Doz. Dr. Reinhard Klein
Fachhochschulprofessor Institut Biotechnologie
Institut Biotechnologie
+43 2732 802 883
[email protected]
IMC Campus KremsIMC Campus Trakt G
Virologie
Molekjularbiologie
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
EvoFerm
Department of Science & Technology
In-Vivo-RNA Interferenzstrategien gegen Adenoviren
Projektleitung, Department of Science & Technology
Virale und fungale Infektionen
Projektleitung, Department of Science & Technology
RNA Interferenz als Methode zur Inhibierung von Virusinfektionen
Projektleitung, Department of Science & Technology
Selb, R., Derntl, C., Klein, R., Alte, B., Hofbauer, C., Kaufmann, M., Beraha, J., Schöner, L., & Witte, A. (2017): The Viral Gene ORF79 Encodes a Repressor Regulating Induction of the Lytic Life Cycle in the Haloalkaliphilic Virus ϕCh1. Journal of virology, 91(9): e00206-17.
Doi: https://doi.org/10.1128/JVI.00206-17
Derntl, C., Selb, R., Klein, R., Alte, B., & Witte, A. (2015): Genomic manipulations in alkaliphilic haloarchaea demonstrated by a gene disruption in Natrialba magadii. FEMS microbiology letters, 362(21): fnv179.
Doi: https://doi.org/10.1093/femsle/fnv179
Derntl, C., Selb, R., Klein, R., Alte, B., & Witte, A. (2015): Genomic manipulations in alkaliphilic haloarchaea demonstrated by a gene disruption in Natrialba magadii. FEMS microbiology letters, 362(21): fnv179.
Doi: https://doi.org/10.1093/femsle/fnv179
Bellutti, F., Kauer, M., Kneidinger, D., Lion, T., & Klein, R. (2015): Identification of RISC-associated adenoviral microRNAs, a subset of their direct targets, and global changes in the targetome upon lytic adenovirus 5 infection. Journal of virology, 89(3): 1608–1627.
Doi: https://doi.org/10.1128/JVI.02336-14
Bellutti, F., Kauer, M., Kneidinger, D., Lion, T., & Klein, R. (2015): Identification of RISC-associated adenoviral microRNAs, a subset of their direct targets, and global changes in the targetome upon lytic adenovirus 5 infection. Journal of virology, 89(3): 1608–1627.
Doi: https://doi.org/10.1128/JVI.02336-14
Ibrišimović, M., Lion, T., & Klein, R. (2013): Combinatorial targeting of 2 different steps in adenoviral DNA replication by herpes simplex virus thymidine kinase and artificial microRNA expression for the inhibition of virus multiplication in the presence of ganciclovir. BMC biotechnology, 13(1): 54.
Doi: https://doi.org/10.1186/1472-6750-13-54
Mayrhofer-Iro, M., Ladurner, A., Meissner, C., Derntl, C., Reiter, M., Haider, F., Dimmel, K., Rössler, N., Klein, R., Baranyi, U., Scholz, H., & Witte, A. (2013): Utilization of virus φCh1 elements to establish a shuttle vector system for Halo(alkali)philic Archaea via transformation of Natrialba magadii. Applied and environmental microbiology, 79(8): 2741–2748.
Doi: https://doi.org/10.1128/AEM.03287-12
Ibrišimović, M., Kneidinger, D., Lion, T., & Klein, R. (2013): An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs. Antiviral research, 97(1): 10–23.
Doi: https://doi.org/10.1016/j.antiviral.2012.10.008
Kneidinger, D., Ibrišimović, M., Lion, T., & Klein, R. (2012): Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral research, 94(3): 195–207.
Doi: https://doi.org/10.1016/j.antiviral.2012.03.011
Ibrišimović, M., Nagl, U., Kneidinger, D., Rauch, M., Lion, T., & Klein, R. (2012): Targeted expression of herpes simplex virus thymidine kinase in adenovirus-infected cells reduces virus titers upon treatment with ganciclovir in vitro. The journal of gene medicine, 114(1): 3–19.
Doi: https://doi.org/10.1002/jgm.1638
Klein, R., Rössler, N., Iro, M., Scholz, H., & Witte, A. (2012): Haloarchaeal myovirus φCh1 harbours a phase variation system for the production of protein variants with distinct cell surface adhesion specificities. Molecular microbiology, 83(1): 137–150.
Doi: https://doi.org/10.1111/j.1365-2958.2011.07921.x
Klein, R., Ruttkowski, B., Schwab, S., Peterbauer, T., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2008): Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo. Journal of biomedicine & biotechnology, 2008(683505 ): 10.
Doi: https://doi.org/10.1155/2008/683505
Agu, C. A., Klein, R., Lengler, J., Schilcher, F., Gregor, W., Peterbauer, T., Bläsi, U., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2007): Bacteriophage-encoded toxins: the lambda-holin protein causes caspase-independent non-apoptotic cell death of eukaryotic cells. Cellular microbiology, 9(7): 1753–1765.
Doi: https://doi.org/10.1111/j.1462-5822.2007.00911.x
Iro, M., Klein, R., Gálos, B., Baranyi, U., Rössler, N., & Witte, A. (2007): The lysogenic region of virus phiCh1: identification of a repressor-operator system and determination of its activity in halophilic Archaea. xtremophiles : life under extreme conditions, 11(2): 383–396.
Doi: https://doi.org/10.1007/s00792-006-0040-3
Klein, R., Ruttkowski, B., Knapp, E., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2006): WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene, 372: 153–161.
Doi: https://doi.org/10.1016/j.gene.2005.12.018
Hand, N. J., Klein, R., Laskewitz, A., & Pohlschröder, M. (2006): Archaeal and bacterial SecD and SecF homologs exhibit striking structural and functional conservation. Journal of bacteriology,, 188(4): 1251–1259.
Doi: https://doi.org/10.1128/JB.188.4.1251-1259.2006
Agu, C. A., Klein, R., Schwab, S., König-Schuster, M., Kodajova, P., Ausserlechner, M., Binishofer, B., Bläsi, U., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2006): The cytotoxic activity of the bacteriophage lambda-holin protein reduces tumour growth rates in mammary cancer cell xenograft models. The journal of gene medicine, 8(2): 229–241.
Doi: https://doi.org/10.1002/jgm.833
Mangold, M., Siller, M., Roppenser, B., Vlaminckx, B. J., Penfound, T. A., Klein, R., Novak, R., Novick, R. P., & Charpentier, E. (2004): Synthesis of group A streptococcal virulence factors is controlled by a regulatory RNA molecule. Molecular microbiology, 53(5): 1515–1527.
Doi: https://doi.org/10.1111/j.1365-2958.2004.04222.x
Rössler, N., Klein, R., Scholz, H., & Witte, A. (2004): Inversion within the genome of the haloalkaliphilic virus phiCh1 results in differential expression of structural proteins. Molecular microbiology, 52(2): 413–426.
Doi: https://doi.org/10.1111/j.1365-2958.2003.03983.x
Klein, R., Baranyi, U., Rössler, N., Greineder, B., Scholz, H., & Witte, A. (2002): Natrialba magadii virus fCh: First complete nucleotide sequence and functional organization of a virus infecting an extreme haloalkaliphilic archaeon. Molecular microbiology, 45(3): 851–863.
Doi: https://doi.org/10.1046/j.1365-2958.2002.03064.x
Klein, R., Greineder, B., Baranyi, U., & Witte, A. (2000): The structural protein E of the archaeal virus phiCh1: evidence for processing in Natrialba magadii during virus maturation. Virology, 276(2): 376–387.
Doi: https://doi.org/10.1006/viro.2000.0565
Baranyi, U., Klein, R., Lubitz, W., Krüger, D. H., & Witte, A. (2000): The archaeal halophilic virus-encoded Dam-like methyltransferase M. phiCh1-I methylates adenine residues and complements dam mutants in the low salt environment of Escherichia coli. Molecular microbiology, 35(5): 1168–1179.
Doi: https://doi.org/10.1046/j.1365-2958.2000.01786.x
Katinger, A., Lubitz, W., Szostak, M. P., Stadler, M., Klein, R., Indra, A., Huter, V., & Hensel, A. (1999): Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. Journal of biotechnology, 73(2-3): 251–260.
Doi: https://doi.org/10.1016/s0168-1656(99)00143-1
Witte, A., Baranyi, U., Klein, R., Sulzner, M., Luo, C., Wanner, G., Krüger, D. H., & Lubitz, W. (1997): Characterization of Natronobacterium magadii phage phi Ch1, a unique archaeal phage containing DNA and RNA. Molecular microbiology, 23(3): 603–616.
Doi: https://doi.org/10.1046/j.1365-2958.1997.d01-1879.x
Szostak, M. P., Hensel, A., Eko, F. O., Klein, R., Auer, T., Mader, H., Haslberger, A., Bunka, S., Wanner, G., & Lubitz, W. (1996): Bacterial ghosts: non-living candidate vaccines. Journal of biotechnology, 44(1-3): 161–170.
Doi: https://doi.org/10.1016/0168-1656(95)00123-9
Prof.(FH) Priv.Doz. Dr. Reinhard Klein
Fachhochschulprofessor Institut Biotechnologie
Prof.(FH) Dr. Christian Klein
Fachhochschulprofessor Institut Biotechnologie
Institut Biotechnologie
+43 2732 802 522
[email protected]
IMC Campus KremsIMC Campus Trakt G
Wirkstoffdesign
Biochemische Systemtheorie
Molecular Modelling und Chemoinformatik
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Applied Chemistry
Bachelor of Science in Engineering / Vollzeit
EvoFerm
Department of Science & Technology
Spike-Fermentation
Department of Science & Technology
Entwicklung von therapeutischen Peptiden für Krebs- und regenerative Medizin
Department of Science & Technology
Entwicklung einer Design-Pipeline für innovative Protein-Protein-Interaktionshemmer
Projektleitung, Department of Science & Technology
Entwicklung neuer immunregulierender Peptide und geschlechtsspezifischer organotypischer Zellmodelle für humane Sepsis
Department of Science & Technology
Funktionale Validierung prädiktiver Biomarker für zielgerichtete Krebstherapien
Department of Science & Technology
Stierschneider, A., Grünstäudl, P., Colleselli, K., Atzler, J., Klein, C., Hundsberger, H., Wiesner, C. (2021): Light-Inducible Spatio-Temporal Control of TLR4 and NF-κB-Gluc Reporter in Human Pancreatic Cell Line. International Journal of Molecular Sciences, 22(17): 9232.
Doi: https://doi.org/10.3390/ijms22179232
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Ablinger, C., Geisler, S. M., Stanika, R. I., Klein, C. T., & Obermair, G. J. (2020): Neuronal α2δ proteins and brain disorders. Pflugers Archiv : European journal of physiology, 472(7): 845-863.
Doi: https://doi.org/10.1007/s00424-020-02420-2
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Volk, K., Breunig, S. D., Rid, R., Herzog, J., Bräuer, M., Hundsberger, H., Klein, C., Müller, N., & Önder, K. (2017): Structural analysis and interaction studies of acyl-carrier protein (acpP) of Staphylococcus aureus, an extraordinarily thermally stable protein. Biological chemistry, 398(1): 125-133.
Doi: https://doi.org/10.1515/hsz-2016-0185
Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7
Jacobi, N., Smolinska, V., Stierschneider, A., Klein, C., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2016): Development of organotypic cancer models for the identification of individualized cancer therapies. In FH des BFI Wien (Hrsg.), Online-Tagungsband FHK Forschungsforum 2016. Wien: FFH.
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C.T., Kraemer, O., Himmelsbach, F., Haaksma, E., Adolf, G. R. (2012): Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. Journal of Pharmacology and Experimental Therapeutics, 343(2): 342-350.
Doi: https://doi.org/10.1124/jpet.112.197756
Klein, C.T., Kaiser, D., Ecker, G. (2004): 3D Topolgical Distance-Based Descriptors for Use in QSAR and Diversity Analysis. Journal of Chemical Information and Computer Sciences, 44(1): 200-209.
Doi: https://doi.org/10.1021/ci0256236
Klein, C.T., Kaiser, D., Kopp, S., Chiba, P., Ecker, G. (2002): Similarity-Based SAR as Tool for Early ADME Profiling. Journal of Computer-Aided Molecular Design, 16: 785-793.
Doi: https://doi.org/10.1023/A:1023828527638
Klein, C.T., Kaiblinger, N., Wolschann, P. (2002): Internally Defined Distances in 3D-Quantitative Structure-Activity Relationships. Journal of Computer-Aided Molecular Design, 16: 79-93.
Doi: https://doi.org/10.1023/A:1016308417830
Mayer, B., Klein, C.T. (2000): Influence of Solvation on the Helix Forming Tendency of Nonpolar Amino Acids. Journal of Molecular Structure: THEOCHEM, 532(1-3): 213-226.
Doi: https://doi.org/10.1016/S0166-1280(00)00559-5
Buchbauer, G., Klein, C.T., Wailzer, B., Wolschann, P. (2000): Threshold-Based Structure-Activity Relationships of Pyrazines with Bell Pepper Flavor. Journal of Agricultural and Food Chemistry, 48(9): 4273-4278.
Doi: https://doi.org/10.1021/jf000192h
Klein, C.T., Polheim, D., Viernstein, H., Wolschann, P. (2000): A Method for Estimation of the Free Energies of Complexation between ß-Cyclodextrin and Guest Molecules. Journal of Inclusion Phenomena, 36(4): 409-423.
Doi: https://doi.org/10.1023/A:1008063412529
Klein, C.T., Pircher, H., Wailzer, B., Buchbauer, G., Wolschann, P. (2000): Quantitative Structure-Property Study on Pyrazines with Bell Peper Flavor. Scientific Pharmaceutica, 68(1): 41-56.
Doi: https://doi.org/10.3797/scipharm.aut-00-04
Klein, C.T., Lawtrakul, L., Hannongbua, S., Wolschann, P. (2000): Accessible Charges as Sensitive Descriptors in Structure-Activity Relationships. A Study on HEPT-based HIV-1 RT Inhibitors. Scientific Pharmaceutica, 68(1): 25-40.
Doi: https://doi.org/10.3797/scipharm.aut-00-03
Klein, C.T., Viernstein, H., Wolschann, P. (2000): Free Energy Prediction of Complexation between ß-Cyclodextrin and Guest Molecules: External Predictivity of MR and PLS Models. Scientific Pharamaceutica, 68(1): 15-24.
Doi: https://doi.org/10.3797/scipharm.aut-00-02
Klein, C.T., Polheim, D., Viernstein, H., Wolschann, P. (2000): Predicting the Free Energies of Complexation between Cyclodextrins and Guest Molecules: Linear versus Nonlinear Models. Pharamaceutical Research, 17: 358-365.
Doi: https://doi.org/10.1023/A:1007565409407
Mayer, B., Klein, C.T., Köhler, G. (1999): Selective Assembly of Cyclodextrins on Poly(ethylene oxide) Poly(propylene oxide) Copolymers. Journal of Computer-Aided Molecular Design, 13: 373-383.
Doi: https://doi.org/10.1023/A:1008095501870
Klein, C.T., Mayer, B. (1999): Sources for Switches and Structure Formation in Metabolic Pathways. Biosystems, 51(1): 41-52.
Doi: https://doi.org/10.1016/S0303-2647(99)00012-X
Klein, C.T., Mayer, B., Köhler, G., Wolschann, P. (1998): Systematic Stepsize Variation: An Efficient Method for Searching the Conformational Space of Polypeptides. Journal of Computational Chemistry, 19(13): 1470-1481.
Doi: https://doi.org/10.1002/(SICI)1096-987X(199810)19:13<1470::AID-JCC4>3.0.CO;2-N
Klein, C.T. (1998): Hysteresis-Driven Pattern Formation in Biochemical Networks. Journal of Theoretical Biology, 194(2): 263-274.
Doi: https://doi.org/10.1006/jtbi.1998.0757
Mayer, B., Marconi, G., Klein, C.T., Köhler, G., Wolschann, P. (1997): Structural Analysis of Host–Guest Systems. Methyl-substituted Phenols in beta;-Cyclodextrin. Journal of inclusion phenomena and molecular recognition in chemistry, 29: 79-93.
Doi: https://doi.org/10.1023/A:1007920606983
Klein, C.T., Mayer, B. (1997): A Model for Pattern Formation in Gap-Junction Coupled Cells. Journal of Theoretical Biology, 186(1): 107-115.
Doi: https://doi.org/10.1006/jtbi.1996.0337
Grabner, G., Monti, S., Marconi, G., Mayer, B., Klein, C.T., Köhler, G. (1997): Spectroscopic and Photochemical Study of Inclusion Complexes of Dimethoxybenzenes with Cyclodextrins. The Journal of Physical Chemistry , 100(51): 20068-20075.
Doi: https://doi.org/10.1021/jp962231r
Marconi, G., Mayer, B., Klein, C.T., Köhler, G. (1996): The structure of higher order C60-fullerene-γ-cyclodextrin complexes. Chemical Physics Letters, 260(5-6): 589-594.
Doi: https://doi.org/10.1016/0009-2614(96)00915-3
Köhler, G., Grabner, G., Klein, C.T., Marconi, G., Mayer, B., Monti, S., Rechthaler, K., Rotkiewicz, K., Viernstein, H., Wolschann, P. (1996): Structure and spectroscopic Properties in Cyclodextrin Inclusion Complexes. In Szejtli, J., Szente, L. (Hrsg.), Proceedings of the Eighth International Symposium on Cyclodextrins (215-220). Budapest, Hungary: Springer, Dordrecht.
Doi: https://doi.org/10.1007/978-94-011-5448-2_46
Klein, C.T., Mayer, B., Köhler, G., Wolschann, P. (1996): Influence of solvation on helix formation of poly-alanine studied by multiple annealing simulations. Journal of Molecular Structure: THEOCHEM, 372(1): 33-43.
Doi: https://doi.org/10.1016/S0166-1280(96)04745-8
Klein, C. T., & Seelig, F. F. (1995): Turing structures in a system with regulated gap-junctions. Bio Systems, 35(1): 15–23.
Doi: https://doi.org/10.1016/0303-2647(94)01478-p
Klein, C.T., Mayer, B., Köhler, G., Mraz, K., Reiter, S., Viernstein, H., Wolschann, P. (1995): Solubility and Molecular Modeling of Triflumizole-ß-cyclodextrin Inclusion Complexes. Journal of inclusion phenomena and molecular recognition in chemistry, 22: 15–32.
Doi: https://doi.org/10.1007/BF00706495
Prof.(FH) Dr. Christian Klein
Fachhochschulprofessor Institut Biotechnologie
Prof.(FH) DI Bernhard Klausgraber
Fachhochschulprofessor Institut Biotechnologie
Institut Biotechnologie
+43 2732 802 348
[email protected]
IMC Campus KremsIMC Campus Trakt G
Anorganische und Organische Chemie
Mikrobiologie
Fermentationsentwicklung und Optimierung
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Synthese und industrielle Verwendung von Hydroxytyrosol
Department of Science & Technology
Extremophiles
Projektleitung, Department of Science & Technology
Co-Kultivierung von Mikroorganismen
Department of Science & Technology
Etablierung innovativer humaner Tumor-Mimetika für das Screening von bioaktiven Wirkstoffen
Department of Science & Technology
Prof.(FH) DI Bernhard Klausgraber
Fachhochschulprofessor Institut Biotechnologie
Prof.(FH) Dr. Barbara Entler
Fachhochschulprofessorin Institut Biotechnologie
Institut Biotechnologie
+43 2732 802 361
[email protected]
IMC Campus KremsIMC Campus Trakt G
Mikrobiologie
Mikrobielles Monitoring
Gentechnik
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
EvoFerm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Moritz, B., Locatelli, V., Niess, M., Bathke, A., Kiessig, S., Entler, B., Finkler, C., Wegele, H., & Stracke, J. (2017): Optimization of capillary zone electrophoresis for charge heterogeneity testing of biopharmaceuticals using enhanced method development principles. Electrophoresis, 38(24): 3136–3146.
Doi: https://doi.org/10.1002/elps.201700145
Wiesner, C., Pflueger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schuett, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene interdisziplinar, 3(1).
Wiesner, C., Pflüger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schütt, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene Interdisziplinär, 3(1): Doc05.
Wiesner, C., Lucas, R., Pflueger, M., Kleber, C., Kopecky, J., Stys, D., Entler, B., Hundsberger, H., Atzler, J., Hrouzek, P., Lukesova, A., Schuett, W., (2007): Endothelial Cell-Based Methods for the Detection of Cyanobacterial Anti- Inflammatory and Wound-Healing Promoting Metabolites. Drug Metabolism Letters, 1(4): 254-260.
Doi: https://doi.org/10.2174/187231207783221385
Prof.(FH) Dr. Barbara Entler
Fachhochschulprofessorin Institut Biotechnologie
Hon.Prof.(FH) Mag. Alfred Siedl
Lecturer Institut Betriebswirtschaft und Management
Institut Betriebswirtschaft und Management
+43 2732 802
[email protected]
Statistik, Wirtschaftsmathematik
MS Office, SPSS, GeoGebra
Betriebswirtschaft für das Gesundheitswesen
Bachelor of Arts in Business / Vollzeit
Betriebswirtschaft für das Gesundheitswesen
Bachelor of Arts in Business / Berufsbegleitend
Tourism and Leisure Management
Bachelor of Arts in Business / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Business Administration
Bachelor of Arts in Business / Vollzeit
Hon.Prof.(FH) Mag. Alfred Siedl
Lecturer Institut Betriebswirtschaft und Management
Dipl.-Ing. Dr. Franz Herzog
Stiftungsprofessur /Leiter Massenspektrometrie / Institute Krems Bioanalytics
Institute Krems Bioanalytics
+43 2732 802 218
[email protected]
IMC TFZIMC TFZ Haupthaus (Verwaltungsgebäude 1)
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / Vollzeit
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / Vollzeit
Stierschneider, A., Neuditschko, B., Colleselli, K., Hundsberger, H., Herzog, F., & Wiesner, C. (2023): Comparative and Temporal Characterization of LPS and Blue-Light-Induced TLR4 Signal Transduction and Gene Expression in Optogenetically Manipulated Endothelial Cells. Cells, 12(697).
Doi: https://doi.org/10.3390/cells12050697
Koehnke, T., Liu, X., Haubner, S., Buecklein, V., Haenel, G., Krupka, C., Solis-Mezarino, V., Herzog, F., Subklewe, M. (2022): Integrated multiomic approach for identification of novel immunotherapeutic targets in AML. Biomarker Research, 10(1): 43.
Doi: https://doi.org/10.1186/s40364-022-00390-4
Dipl.-Ing. Dr. Franz Herzog
Stiftungsprofessur /Leiter Massenspektrometrie / Institute Krems...

Zulassung & Aufnahme – die nächsten Schritte

Sie haben einen Studiengang gefunden, der perfekt zu Ihnen passt? Sehr gut – das Wichtigste ist damit schon geschafft. Informieren Sie sich jetzt über die nächsten Schritte. Wir haben alle relevanten Informationen für Sie zusammengefasst.

Welche Zugangsvoraussetzungen gelten für unsere Master-Studiengänge?

Ein Master-Studium setzt voraus, dass Sie zuvor ein facheinschlägiges Bachelor-Studium oder ein gleichwertiges Studium mit mindestens 6 Semestern und 180 ECTS an einer anerkannten in- oder ausländischen postsekundären Bildungseinrichtung absolviert haben.

Wenn die Facheinschlägigkeit Ihres Grundstudiums nicht eindeutig gegeben ist – wenn also zum Beispiel ein fachfremdes Studium im Vorfeld absolviert wurde –, werden Ihre Qualifikationen nach Einlangen der vollständigen Bewerbungsunterlagen durch die zuständigen Stellen im Detail geprüft.

Informationen über zulässige Vorstudien

Wichtig
Steht Ihnen der Präsenz- beziehungsweise Zivildienst noch bevor? Als männlicher Bewerber mit österreichischer Staatsbürgerschaft empfehlen wir Ihnen dringend, die Wehrpflicht noch vor dem Studium abzuleisten. So können Sie Ihr Studium ohne Unterbrechung durchführen und direkt nach dem Studium in das Berufsleben einsteigen.

Aufnahmegespräch

Bei unseren Master-Studiengängen steht die Person im Mittelpunkt. Deshalb möchten wir Sie im Aufnahmeverfahren gerne persönlich kennenlernen.

Im Rahmen der Online-Bewerbung ist ein Motivationsschreiben zu verfassen. Vorgegebene Fragen zu Ihren Beweggründen finden Sie in der Online-Bewerbung. In Ihren Antworten, die Sie in eigens dafür vorgesehene Eingabefelder eintragen, setzen sich mit den Fragestellungen auseinander und erörtern Ihre Studienmotivation. Für Ihr Aufnahmegespräch werden Ihr Motivationsschreiben und Ihr Lebenslauf als Grundlage herangezogen. Das Aufnahmegespräch ist ein Einzelgespräch, in der Regel mit dem Studiengangsleiter bzw. der Studiengangsleiterin.
Neben dem persönlichen Kennenlernen werden Ihre Beweggründe für das Studium besprochen, sowie Ihr fachlicher Background und Ihre bisher erworbenen Kompetenzen diskutiert. Es wird besonders auf Ihre fachlichen Vorkenntnisse, Ihre Methoden- und Sprachkompetenz und Ihre allgemeine Eignung in Hinsicht auf Ihr angestrebtes Master-Studium geachtet.

Das Aufnahmegespräch findet entweder online über Microsoft Teams oder Vorort statt und wird in der Unterrichtssprache des Studiengangs geführt.

Welche Aufnahmetermine gibt es?

Sie haben in der Regel die Wahl zwischen mehreren Aufnahmetagen, die mit Kontingenten hinterlegt sind. Im Zuge der Online-Bewerbung können Sie Ihren bevorzugten Termin auswählen. Um noch von der vollen Auswahl an Terminen profitieren zu können, empfehlen wir Ihnen, Ihre Bewerbung rechtzeitig durchzuführen.

Verschaffen Sie sich jetzt einen Überblick über die für Sie relevanten Termine:

Aufnahmegespräch

01.06.202315.06.202327.06.202305.07.202318.07.2023

Nachdem Sie Ihre Online Bewerbung erfolgreich abgeschlossen haben, wird Ihre Bewerbung auf Vollständigkeit und Richtigkeit geprüft. Sobald dieser Vorgang abgeschlossen ist, informieren wir Sie per E-Mail und bestätigen dabei auch den Aufnahmetermin.

Ende der Bewerbungsfrist für EU StaatsbürgerInnen / Nachfrist	15.05.2023 / 15.08.2023
Ende der Bewerbungsfrist für Nicht-EU StaatsbürgerInnen Bewerbung für das nächste Studienjahr möglich ab 01.12.2023	15.04.2023

Bitte berücksichtigen Sie, dass sich die IMC Fachhochschule Krems eine frühzeitige Beendigung der Nachfrist ohne Vorankündigung vorbehält. Wir empfehlen Ihnen daher Ihre Bewerbung so rasch wie möglich einzureichen.

Jetzt bewerben

Sie haben sich für einen unserer Studiengänge entschieden? Zuerst einmal: Gratulation und vielen Dank für Ihr Vertrauen! Gerne führen wir Sie Schritt für Schritt durch Ihre Online-Bewerbung.

Details

Sie planen gerne voraus und möchten wissen, wann Ihr Studiengang startet? Hier werden Sie fündig!

Details

Fragen zum Studienangebot?

Studienberatung

Sie haben Fragen zu den Zugangsvoraussetzungen, zum Aufnahmeverfahren und Co? Unsere Studienberatung hilft Ihnen gerne weiter.

+432732802222

[email protected]

Ask a Student

Richten Sie Ihre Fragen direkt an unsere Studierenden und holen Sie sich Erfahrungen aus erster Hand. Unsere Facebook-Gruppe macht es möglich.

Zur Facebook-Seite

Ask Johanna

Sie möchten Informationen aus erster Hand zum Studiengang Medical and Pharmaceutical Biotechnology? Kontaktieren Sie Johanna direkt, sie beantwortet Ihnen gerne alle Fragen zum Studium.

[email protected]

Diese Studiengänge könnten Sie auch interessieren

Digital Business Innovation and Transformation

Mit dem Master-Studiengang Digital Business Innovation and Transformation können Sie digitale Transformationen in sämtlichen Branchen koordinieren.

Details anzeigen

Master-Studiengang Medical and Pharmaceutical Biotechnology

Das Studium

Erfolgskonzept: Theorie + Praxis

1. Die Kernbereiche

2. Die Spezialisierungen

3. Das Research Semester und die Master-Arbeit

Studienplan

Immunology

Hallmarks of Cancer

Molecular Mechanisms of Ageing

Developmental Biology

Bioethics

Equipment and Production Design

Standardization

Legislation for Drugs and Medical Devices

Upstream Processing

Downstream Processing

Recombinant Protein Production - Theory

Recombinant Protein Production - Laboratory

Research Project - Preparation

Process Control and Process Online Monitoring

Drug Discovery Systems

Biostatistics and Trend Analysis

Systems Biology

Structural Bioinformatics and Drug Design

Bioanalytics Laboratory

Personalized Medicine Laboratory

Analytical Methods in Biomedicine

Pharmacokinetics and Pharmacodynamics

GLP and GMP Regulations

Risk Assessment

Quality Management Systems

Project and Portfolio Management

Clinical Studies and GCP

Entrepreneurship in Life Sciences

Fermentation of Complex Host Systems

Scale Up - Scale Down Techniques

Fermentation Technology - Laboratory I

Advanced Therapeutic Development Laboratory I

Pathophysiology and Molecular Therapies

Equipment Test and Process Validation

Fermentation Technology - Laboratory II

Stem Cells, Gene Therapy and Regenerative Medicine

Immunology Based Therapies

Advanced Therapeutic Development Laboratory II

Master Thesis - Part I

Master Thesis - Coaching Seminar I

Research Project

Current Issues in Bioprocess Engineering

Current Issues in Advanced Therapeutic Development

Master Thesis - Part II

Master Thesis - Coaching Seminar II

Master Exam

Spezialisierungen

Bioprocess Engineering

Advanced Therapeutics Development

Newsletter & Infomaterial

Newsletter & Infomaterial

Karrierewege nach dem Master-Studium Medical and Pharmaceutical Biotechnology

Im Fokus: Medical and Pharmaceutical Biotechnology

Info-Veranstaltungen

Virtual Master Talks

Open House 2024

Unser Team

Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger

Institutsleitung Biotechnologie / Studiengangsleitung Medical and Pharmaceutical Biotechnology

Kernkompetenzen

DI (FH) Anita Koppensteiner

Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger

Prof.(FH) Mag. Dr. Christoph Wiesner

Prof.(FH) DI Dominik Schild

Prof.(FH) Mag. Dana Mezricky

Prof.(FH) Priv.Doz. Dr. Reinhard Klein

Prof.(FH) Dr. Christian Klein

Prof.(FH) DI Bernhard Klausgraber

Prof.(FH) Dr. Barbara Entler

Hon.Prof.(FH) Mag. Alfred Siedl

Dipl.-Ing. Dr. Franz Herzog

Zulassung & Aufnahme – die nächsten Schritte

Welche Zugangsvoraussetzungen gelten für unsere Master-Studiengänge?